Podcasts about Chief scientific officer

Peter A McCullough, MD, MPH, Chief Scientific Officer, TWC. Visit twc.health/GRUBER and use Promo Code: GRUBER Secretary Kennedy announced the removal of the COVID vaccine from the CDC's recommended schedule, for 'healthy children and healthy pregnant women."

All Home Care Matters and our host, Lance A. Slatton were honored to welcome the team behind the Dementia Care Family Support Program.   About Denise M. Brown:   Denise began supporting family caregivers in 1990, launching one of the first online caregiving communities in 1996. She trains Caregiving Consultants, Facilitators, Guides and Navigators. She cared for her father for almost 20 years and for her mother for 8 years.   She's written 16 books for current and former family caregivers.    About Dr. Laura Gitlin:   Dr. Laura Gitlin is the Co-founder and Chief Scientific Officer at Plans4Care. She is an intervention scientist with over 40 years of experience in dementia care and research. Dr. Gitlin currently serves as a multiple Principal Investigator on several NIH-funded grants, where she leads the development and testing of innovative interventions to support people living with dementia and their caregivers.   About Eric Jutkowitz, PhD:   Eric Jutkowitz, PhD is the Co-founder and CEO of Plans4Care. He is health services focused on improving the nation's long-term care system. He co-founded Plans4Care to bring evidence-based dementia care out of the university and into the hands of all family caregivers.   About the Dementia Care Family Support Program:   Our Certified Caregiving Consultants partnered with Plans4Care, a technology start-up to offer 5 coaching sessions to dementia family caregivers in order to resolve 3 care challenges.   We'll share what we learned about using technology during coaching sessions, the common care challenges we addressed and the insights we gained from tracking our coaching sessions. We also will talk about what we learned about how to best support dementia family caregivers to help ease their stress and worries.

On this episode of The Kara Goldin Show, we're joined by Catharine Arnston, Founder, CEO, and Chief Scientific Officer of ENERGYbits®—the pioneering brand bringing the power of algae to the forefront of wellness, energy, and longevity. After a deeply personal experience with a family health crisis, Catharine made it her mission to educate the world about the incredible health benefits of spirulina and chlorella—long before they became trendy.In our conversation, Catharine shares the early days of discovering algae's healing potential, what inspired her to build ENERGYbits, and why she believes algae is the most powerful superfood on the planet. We dive into the science behind spirulina and chlorella, the major obstacles she faced educating consumers, and how she's grown ENERGYbits into a trusted brand used by athletes, biohackers, and wellness seekers worldwide. Catharine also opens up about the resilience it takes to build a movement from scratch, the leadership lessons she's learned, and the habits that keep her going strong.Whether you're a health-focused founder, a nutrition enthusiast, or someone curious about building brands with real mission and impact, this episode is packed with insights you won't want to miss. Now on The Kara Goldin Show. Are you interested in sponsoring and advertising on The Kara Goldin Show, which is now in the Top 1% of Entrepreneur podcasts in the world? Let me know by contacting me at karagoldin@gmail.com. You can also find me @‌KaraGoldin on all networks. To learn more about Catharine Arnston and ENERGYbits®:https://www.instagram.com/energybitshttps://www.linkedin.com/in/catharinearnstonhttps://www.youtube.com/energybitshttps://www.facebook.com/ENERGYbitshttps://www.twitter.com/energybitshttps://www.instagram.com/catharinearnston/https://www.energybits.com Sponsored By:Range Rover Sport - The Range Rover Sport is your perfect ride. Visit RangeRover.com/us/Sport and check it out. Check out our website to view this episode's show notes: https://karagoldin.com/podcast/692

Peter A McCullough, MD, MPH, Chief Scientific Officer, TWC. twc.health/GRUBER. Promo Code GRUBER Saves 10% What came out at the WED May 21 Senate Hearing on Vaccine Myocarditis?

Blockchain Ireland's annual conference serving the blockchain, crypto and Web3 communities, Blockchain Ireland Summit 2025 kicks off this Friday. One of the speakers at the two day conference is Richard Blythman the Co-founder and Chief Scientific Officer of Naptha.AI, a startup building open, decentralised infrastructure for the next generation of AI. Richard's background is in machine learning, engineering, and academic research, and his work focuses on enabling developers to build intelligent agents that can work together, without relying on centralised platforms or Big Tech infrastructure. Ronan recently caught up with Richard. Richard talks about his background, the internet of agents, what naptha does, AI privacy, eu regulation and more.More about Richard Blythman:He previously co-founded Algovera, one of the earliest players in the decentralised AI sector, and holds a PhD in Engineering from Trinity College Dublin. His experience spans from building generative models and digital avatars in Big Tech, to leading research on fluid dynamics, multi-agent coordination, and privacy-preserving AI systems.At Naptha, Richard is exploring how decentralised agent networks could reshape everything from software development to data ownership, and why open standards like MCP are key to unlocking that future.

Today, we have another episode in our series of thoughtfully curated companies. This episode is sponsored by OneSkin, a company founded and led by an all-female team of PhD-level scientists. OneSkin is redefining how we think about aging, starting with the skin, our largest organ. I am delighted to introduce Dr. Alessandra Zonari as our guest today. Dr. Zonari is far from your typical scientist. She is a true visionary with a passion for longevity, skin regeneration, and an occasional karaoke jam. With degrees in biology and stem cell biology and a doctorate in skin regeneration and tissue engineering, Dr. Zonari brings a wealth of knowledge and a fresh perspective to our conversation today. Join us to learn more about OneSkin and how their products can reverse the effects of biological aging, helping your skin become stronger and more resilient as you age. IN THIS EPISODE YOU WILL LEARN: Dr. Zonari shares her mission to understand how skin can age healthier and stronger and reduce the risk of inflammation and diseases.  How the female-led research team at OneSkin brings a unique perspective to skincare How the OneSkin peptide can reverse 2.5 years of biological aging in just five days The unique way in which they test their products and measure biological aging at OneSkin  How estradiol loss during menopause exacerbates the accumulation of senescent cells and causes inflammation Some common misconceptions about skincare for women in perimenopause and menopause How lifestyle choices influence the aging process of the skin  Why we must protect the skin from environmental stressors to slow the aging process  How your skin cells can get reprogrammed to return to a youthful state How OneSkin developed a hair care line to address hair loss and thinning The importance of self-love and nourishing your body  ABOUT OneSkin:  Founded and led by an all-woman team of PhD-level scientists, OneSkin is transforming the way we think about aging, starting with the body's largest organ, the skin. Our proprietary OS-01 (oh ess one) peptide is the first ingredient to reverse the biological age of skin by targeting cellular senescence, a key driver of aging. By targeting cellular senescence, the OS-01 peptide switches off the damaged cells that contribute to lines, wrinkles, and sagging skin. The result? Skin that looks and behaves younger. Our products are designed for young and mature skin, because it is never too early or too late to invest in your skin health! We create next-level skin care. BIO: Alessandra Zonari, PhD, OneSkin Co-Founder & CSO Alessandra is not your typical scientist. She is a visionary with a passion for longevity, skin regeneration, and the occasional karaoke jam. Growing up in a close-knit family in Brazil, Alessandra saw her grandparents struggle with age-related diseases, and she soon became fascinated by the possibility of using stem cells to redefine the aging process. After earning degrees in biology and stem cell biology and a doctorate in skin regeneration and tissue engineering, Alessandra joined OneSkin in 2017 as a founding member and Chief Scientific Officer. Her contributions include 20+ papers, three patents, and the development of their proprietary OS-01 peptide. Connect with Cynthia Thurlow   Follow on X Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Dr. Alessandra Zonari On the ONESKIN website ONESKIN on Instagram Interested in trying OneSkin for yourself? Visit oneskin.co/CYNTHIA and use code CYNTHIA for 15% off your first purchase!

Prime Minister Mark Carney unveiled his new cabinet this week, but he won't be unveiling a budget this year — a move that drew plenty of criticism from his opponents. Newly appointed Industry Minister Melanie Joly joins The House to discuss the decision and weighs in on the new government's other economic priorities. Then, two Hill watchers offer their takes on whether Carney's cabinet picks deliver on his promise for change.Plus, weeks after the election, dramatic recounts are still underway in a handful of ridings, and those results could shake up the House of Commons even further. An elections expert explains what's happening and whether the flip-flopping risks undermining confidence in elections.Finally, measles cases are rising in some parts of the country and provinces are under fire for not doing enough to keep the public better informed. Two doctors talk to Catherine Cullen about what can happen when politics and a deadly disease collide.This episode features the voices of:Melanie Joly, Minister of IndustryShannon Proudfoot, writer for The Globe and Mail's Ottawa bureauPaul Wells, author and podcasterHolly Ann Garnett, associate professor of the Royal Military College of CanadaDr. James Talbot, former Chief Medical Officer of Health for AlbertaDr. Kumanan Wilson, Chief Scientific Officer of Bruyère Health Research Institute

Episode 051 | Greg Maguire, PhD is the Co-Founder of the SRM Living Foundry at UCSD in San Diego and the Co-Founder & Chief Scientific Officer of NeoGenesis, a wonderful company I talk with my patients about all the time. If you haven't yet listed to episode 047 featuring Christine Preston, that one pairs delightfully with my conversation with Dr. Maguire.Awarded a prestigious Fulbright-Fogarty Fellowship from the National Institutes of Health, Dr. Maguire managed his NIH funded laboratory at UCSD studying tissue degeneration and regeneration, and the role of stem cell released molecules (SRM) through paracrine and autocrine actions to maintain, repair, and regenerate human tissues. His NIH funded studies of systems biology and reverse engineering at UC Berkeley and stem cell biology at UC San Diego led to the development of adult stem cell-based S2RM® technology for the development of therapeutics and medical procedures.Dr. Maguire pursued his graduate training at the University of California, Berkeley, University of Houston, University of Texas, The Marine Biological Labs, Woods Hole, MA, and Cold Spring Harbor Laboratory, NY. He is a former professor of neuroscience and ophthalmology at the University of California, San Diego School of Medicine, a visiting associate professor of physiology at Keio University School of Medicine in Tokyo, Japan, visiting assistant professor of molecular neurobiology at the University of Washington, and a visiting scientist at Massachusetts General Hospital (MGH), at Harvard University.Dr. Maguire has over 100 publications and is currently working on his book entitled, “Spontaneous Stem Cell Healing”.The Above & Beyond Dermatology podcast is grateful to NeoGenesis for the great work they do and for their generous support of this episode. If you're a skin care professional and would like to learn more about helping your customers with NeoGenesis, click here to learn more. If you'd like to learn directly from the NeoGenesis team, text me at 715-391-9774 and I'll be happy to make a warm introduction.Connect with and learn from Greg Maguire & NeoGenesisLearn & Shop NeoGenesisDr. Maguire's Skin Care BlogNeoGenesis Wholesale Partnership for Medical ProfessionalsMore from Dr. Lewellis and Above & Beyond DermatologyNeed a dermatologist? Fill out this short interest form, text or call me at 715-391-9774, or email me at drlewellis@aboveandbeyondderm.com if you'd like to have a no obligation discovery call. I offer in-office visits, house calls, and virtual care in Wisconsin and virtual care in Illinois, Nebraska, and Colorado.Have an idea for a guest or want to be on the show yourself? Send me a text or email, and we'll see if it's a good fit.

This is the latest episode of the free DDW narrated podcast, titled “Cutting-edge tools shaping early-stage drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The use-case for NGS”, “Are organ-chips the future of preclinical research?” and “What spatial biology can tell us about disease and drug discovery”. In the first article, DDW Editor Reece Armstrong speaks to Dr Darrell Green, Lecturer in RNA Biology, Biomedical Research Centre, Norwich Medical School University of East Anglia, about his work using next generation sequencing (NGS) and the areas the technology is impacting within drug discovery and development. In the second article, Diana Spencer catches up with Lorna Ewart, PhD, Chief Scientific Officer of Emulate, about the rise of organ-on-a-chip technology. In the third article, DDW Editor Reece Armstrong speaks to Benedikt Nilges, Head of Technology and Data Analytics at OMAPiX about spatial biology's use in drug discovery and bettering our understanding of disease.

Dr. Paul Moore, Chief Scientific Officer at Zymeworks, focuses on developing targeted therapies, particularly multispecific antibodies and antibody-drug conjugates for hard-to-treat cancers such as gynecological, thoracic, and digestive tract cancers. This approach can target multiple areas on tumor cells and immune cells, potentially overcoming tumor heterogeneity and allowing for immune system modulation. The platform allows for a plug-and-play approach, enabling the development of therapies for oncology and autoimmune diseases.  Paul explains, "So, multispecific antibodies are antibodies. Antibodies traditionally have a single target that they bind, so they're monoclonal and hit a specific target. A lot of excitement is generated for bispecific antibodies, which are engineered to bind two targets. Then with multispecifics, you are trying to broaden even further the number of targets or binding sites you've incorporated into your drug so that you can simultaneously interact with more than one target. The reason that can be important is that allows and facilitates new biology that is not possible for just a monoclonal antibody or a single antibody-targeting drug conjugate."   "Multispecifics open up the opportunity to take two targets that are on different cells, different cell populations. So, you can have a target on a tumor cell you're trying to target. Then you can have a target on an immune cell like a T cell, which you can co-engage. You can bridge a T cell to a binding domain that's on a multispecific with your second specificity, which can bind to the cell.  And what that allows you to do is bring the T cell into the environment of the tumor cell, and through that engagement, the T cell can kill the tumor cell.  So that is the foundation of a lot of excitement in bispecifics." #Zymeworks #Antibodies #MultispecificAntibodies #ADC #AntibodyDrugConjugate #Tumors #Cancer #ImmuneSystem zymeworks.com Download the transcript here

Dr. Paul Moore, Chief Scientific Officer at Zymeworks, focuses on developing targeted therapies, particularly multispecific antibodies and antibody-drug conjugates for hard-to-treat cancers such as gynecological, thoracic, and digestive tract cancers. This approach can target multiple areas on tumor cells and immune cells, potentially overcoming tumor heterogeneity and allowing for immune system modulation. The platform allows for a plug-and-play approach, enabling the development of therapies for oncology and autoimmune diseases.  Paul explains, "So, multispecific antibodies are antibodies. Antibodies traditionally have a single target that they bind, so they're monoclonal and hit a specific target. A lot of excitement is generated for bispecific antibodies, which are engineered to bind two targets. Then with multispecifics, you are trying to broaden even further the number of targets or binding sites you've incorporated into your drug so that you can simultaneously interact with more than one target. The reason that can be important is that allows and facilitates new biology that is not possible for just a monoclonal antibody or a single antibody-targeting drug conjugate."   "Multispecifics open up the opportunity to take two targets that are on different cells, different cell populations. So, you can have a target on a tumor cell you're trying to target. Then you can have a target on an immune cell like a T cell, which you can co-engage. You can bridge a T cell to a binding domain that's on a multispecific with your second specificity, which can bind to the cell.  And what that allows you to do is bring the T cell into the environment of the tumor cell, and through that engagement, the T cell can kill the tumor cell.  So that is the foundation of a lot of excitement in bispecifics." #Zymeworks #Antibodies #MultispecificAntibodies #ADC #AntibodyDrugConjugate #Tumors #Cancer #ImmuneSystem zymeworks.com Listen to the podcast here

CareQuest Institute for Oral Health is a national nonprofit dedicated to creating an oral health care system that is accessible, equitable, and integrated. Learn more about how their advocacy, philanthropy, research, and education are creating a better oral health system at carequest.org/turnonthelights What happens when the power of large language models meets the complexity of modern medicine? In this episode, Eric Horvitz, Chief Scientific Officer of Microsoft, discusses the transformative impact of artificial intelligence in health care, particularly the shift from rule-based systems to data-driven models like GPT-4. He highlights how AI can reduce physician burnout by handling administrative tasks and supporting clinical decision-making. Eric emphasizes the importance of AI collaborating with, rather than replacing, health care professionals to improve diagnostic accuracy and patient safety. He also explores future possibilities, including personalized health companions, intelligent patient portals, and AI-powered tumor board simulations. Overall, he underscores both the exciting potential and the responsibility involved in integrating AI safely and meaningfully into health care. Tune in for a thought-provoking conversation on how AI is transforming health care, from easing clinician burden to reimagining patient care and medical decision-making! Learn more about your ad choices. Visit megaphone.fm/adchoices

Peter A McCullough, MD, MPH, Chief Scientific Officer, The Wellness Company  twc.health/GRUBER | Promo Code GRUBER Saves 10% Spaces Event TONIGHT (5/7) on The Steve Gruber Show X account  RFK Jr announces a new “Take Control of Your Health” campaign "We Need a Great Reset in Health" The need to stockpile prescription medication

We catch up on the tri news and racing from the weekend and give our thoughts on the announcement that the IM World Champs is moving back to Kona. Alison Heather is a former academic professor whose research has focused for over 24 years' on the physiology of steroid hormones and their role in health and disease. She has international recognition for her development of bioassays for the detection of steroid hormones. Alison acts as an advisor to many High Performance Sport Teams including those focusing on female athlete health, triathlon, cycling, running and sports supplements and is currently the Chief Scientific Officer for plasmaide In this conversation, we discuss the supplement Plasmaide, its origins and its benefits for athletes. Dr Heather explains the science behind nitric oxide production, the ingredients in Plasmaide and how it compares to other supplements like beetroot juice. The discussion covers both acute and chronic benefits of Plasmaide, its adaptogenic properties and its influence on carbohydrate metabolism. Dr. Heather also provides practical advice for using Plasmaide safely and effectively, emphasizing the importance of consulting with a healthcare professional before starting any new supplement regimen. (0:00:00) – A weekend of bike crashes (0:09:22) – T100 goes to the Gold Coast in 2026 (0:15:51) – The racing from IM703 Venice and IRONMAN Australia  (0:24:16) – IRONMAN World Champs moves back to Kona (0:40:05) – Dr Alison Heather intro (0:41:38) – Dr Alison Heather LINKS: Dr Alison Heather at https://www.insitugen.com/ Plasmaide at https://plasmaide.com.au/ Live Feisty podcast at https://livefeisty.com/podcasts/feistytriathlon/ironman-goes-backwards-special-world-champs-episode/ Pro Tri News podcast at https://protrinews.buzzsprout.com/1736374/episodes/17067560-episode-217-kona-is-back-with-ironman-ceo-scott-derue 2025 Oceania Triathlon Super-Sprint Championships Runaway Bay at  https://triathlon.org/events/2025-oceania-triathlon-super-sprint-championships-

This week on The Genetics Podcast, Patrick is joined by Madhuri Hegde, SVP and Chief Scientific Officer of Revvity. They discuss Revvity's advances in ultra-rapid clinical-grade sequencing, opportunities, challenges, and global inequities in newborn screening, and the dilemma of resequencing versus long-term data storage.Show Notes: 0:00 Intro to The Genetics Podcast00:59 Welcome to Madhuri01:52 Rebranding Revvity as a healthcare company02:51 Advancements in sequencing and Revvity's projects, including newborn screening tests and clinical ultra-rapid sequencing12:29 Opportunities and challenges for newborn sequencing and global inequity in access17:46 Price of sequencing and data storage versus resequencing considerations21:10 Complexities and nuances of genomic data interpretation23:28 Rethinking data portability and storage across the lifespan26:00 Understanding penetrance and population genetics through lifelong sequencing27:36 Scaling genetic counseling to match advancements and the potential value of chatbots32:45 The promise of proteomics and translating Olink data to the clinic 34:31 Implementing polygenic risk scores in clinical management  37:12 Transitioning from academia to industry and insights into product development38:37 Closing remarksFind out moreRevvity (https://www.revvity.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

Bioscience breakthroughs are transforming lives in Central Ohio. From cutting-edge gene therapies to world-first medical devices, the region's life sciences sector is booming—and saving lives. This week's Columbus Metropolitan Club forum brings together scientific leaders and business innovators to explore how research, investment, and clinical development are coming together to power the next generation of healthcare innovation.  Featuring:  Dr. Frank Agbogbo, Vice President of Process Development, Forge Biologics  Dr. Erandi De Silva, Investment Partner, Drive Capital  Dr. Louise Rodino-Klapac, Executive Vice President, Head of R&D, and Chief Scientific Officer, Sarepta  Robin Sears, President and CEO, LENTECHS  The host is Tyler Allchin, Managing Director, Healthcare, JobsOhio This forum was created in partnership with the 2025 COSI Science Festival, and was sponsored by: Armatus Bio, Battelle, Holder Construction, Ohio Life Sciences, The Ohio State University Wexner Medical Center, and Sarepta. The presenting sponsor of the CMC livestream was The Center for Human Kindness at the Columbus Foundation. Our livestream partner was The Columbus Dispatch. This forum was also supported by The Ellis. This forum was recorded before a live audience at The Ellis in Columbus' historic Italian Village on April 30, 2025. 

MAKE Wellness has expanded its executive team with two industry veterans: Dr. Mark Bartlett as Chief Scientific Officer and Tyler Whitehead in strategic leadership. Bartlett brings 30+ years of nutritional science expertise, while Whitehead previously served as Arbonne CEO and Nu Skin President. Make Wellness City: St. George Address: 169 W 2710 S Cir Suite 202-A Website: https://www.makewellness.com

Episode Summary: In this deeply insightful episode, Dr. Nasha Winters is joined by renowned pediatric neurologist and researcher Dr. Richard Frye. With decades of experience and hundreds of peer-reviewed publications, Dr. Frye shares his groundbreaking work in autism spectrum disorder, particularly its links to mitochondrial dysfunction, neuroinflammation, and metabolic abnormalities.You'll learn how Dr. Frye's clinical and lab research is reshaping the narrative around autism—from a strictly genetic and behavioral model to a more hopeful, treatable biomedical framework.They dive into:The mitochondrial abnormalities often present in children with autismThe role of oxidative stress, folate transport issues, and methylationWhy nutrition and prenatal health matter more than everHow treatments like leucovorin, B12, CoQ10, and lifestyle changes can support better outcomesThe promising intersection of microbiome therapy, metabolic testing, and real-world clinical careThis is a must-listen for clinicians, caregivers, and anyone passionate about innovative approaches to autism care.Guest Bio:Dr Frye is a Harvard trained Child Neurologist who received both an MD and PhD from Georgetown University. Dr. Frye is a national leader in autism spectrum disorder (ASD) research, particularly metabolic disorders, and has authored over 300 publications. He has developed the Metabolic Learning Resource which has recently released The Folate Fix. He is President and Chief Scientific Officer of the Autism Discovery and Treatment Foundation, Chief Medical Officer of the Neurological Health Foundation, Director of Research and Neurologist at the Rossignol Medical Center.

Martin Brenner, CEO and Chief Scientific Officer of iBio, is focused on the untapped potential of therapeutic antibodies for obesity and cardiometabolic diseases. Leveraging AI and machine learning, iBio is streamlining the antibody discovery and optimization process and addressing the need for more complex antibody mechanisms of action. Their lead candidate, iBio 600, is an anti-myostatin antibody designed to address the side effects of muscle mass and bone density loss associated with current GLP-1 therapies. Martin explains, "We can separate this into multiple areas. First of all, there's a predictive model that suggests that there are 5,000 different targets related to disease out there. So, there are 5,000 different possibilities to make medicines. All of the currently approved antibodies target only 92 targets. Even worse, 40% of approved antibodies only target about 10. So you can imagine there's a huge untapped potential of novel targets for which antibodies could be used. The problem is that the technologies must keep up with this to open that novel target space. That is problem number one." "So, as you know, AI has gotten a little bit of a bad reputation over the last few years, and there was a huge hype about this, and I want to be very clear about this. It takes more than 10,000 steps to make a medicine. At iBio, we enable three of these steps with generative AI. So, that does not make us an AI company. That does not make our molecules AI drugs. What it does is it actually makes it possible for us to create medicines that we couldn't do before. So, the way we use AI at iBio is multiplefold. First, we start our discovery process with the epitope steering engine. You have to imagine that drug targets are massive proteins, and only very small regions on these proteins have a biological function. So you want to get your antibody exactly to those regions that cause a biological function."  #iBio #DrugDiscovery #MedAI #Obesity #GLP1 #CardioMetabolicDiseases #Antibodies #AntibodyTherapies #Myostatin iBioinc.com Download the transcript here

Martin Brenner, CEO and Chief Scientific Officer of iBio, is focused on the untapped potential of therapeutic antibodies for obesity and cardiometabolic diseases. Leveraging AI and machine learning, iBio is streamlining the antibody discovery and optimization process and addressing the need for more complex antibody mechanisms of action. Their lead candidate, iBio 600, is an anti-myostatin antibody designed to address the side effects of muscle mass and bone density loss associated with current GLP-1 therapies. Martin explains, "We can separate this into multiple areas. First of all, there's a predictive model that suggests that there are 5,000 different targets related to disease out there. So, there are 5,000 different possibilities to make medicines. All of the currently approved antibodies target only 92 targets. Even worse, 40% of approved antibodies only target about 10. So you can imagine there's a huge untapped potential of novel targets for which antibodies could be used. The problem is that the technologies must keep up with this to open that novel target space. That is problem number one." "So, as you know, AI has gotten a little bit of a bad reputation over the last few years, and there was a huge hype about this, and I want to be very clear about this. It takes more than 10,000 steps to make a medicine. At iBio, we enable three of these steps with generative AI. So, that does not make us an AI company. That does not make our molecules AI drugs. What it does is it actually makes it possible for us to create medicines that we couldn't do before. So, the way we use AI at iBio is multiplefold. First, we start our discovery process with the epitope steering engine. You have to imagine that drug targets are massive proteins, and only very small regions on these proteins have a biological function. So you want to get your antibody exactly to those regions that cause a biological function."  #iBio #DrugDiscovery #MedAI #Obesity #GLP1 #CardioMetabolicDiseases #Antibodies #AntibodyTherapies #Myostatin iBioinc.com Listen to the podcast here

Congressman Glenn Grothman from Wisconsin sheds light on the pressing issues surrounding immigration and judicial reform. Grothman discusses the alarming trend of unaccompanied migrant children going missing and criticizes the Democratic Party's stance on illegal immigration. He also addresses the challenges within the judiciary, highlighting concerns about radical judges and the impact of their decisions on American law. Additional interview with Dr. Peter McCullough, Chief Scientific Officer at The Wellness Company, who sounds the alarm on the rise of autism rates in America, as highlighted by HHS Secretary RFK Jr. and supported by new data. Finally, Senior policy analyst Andrés Martínez-Fernández from the Heritage Foundation provides insights on President Trump's recent meeting with El Salvador's President Nayib Bukele, focusing on their agreement to address the challenges of illegal immigration and criminal activity in the U.S.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Guest Bio:  Dave Snowden divides his time between two roles: founder & Chief Scientific Officer of Cognitive Edge and the founder and Director of the Centre for Applied Complexity at the University of Wales.  Known for creating the sense-making framework, Cynefin, Dave's work is international in nature and covers government and industry looking at complex issues relating to strategy, organisational decision making and decision making.  He has pioneered a science-based approach to organisations drawing on anthropology, neuroscience and complex adaptive systems theory.  He is a popular and passionate keynote speaker on a range of subjects, and is well known for his pragmatic cynicism and iconoclastic style. He holds positions as extra-ordinary Professor at the Universities of Pretoria and Stellenbosch and visiting Professor at Bangor University in Wales respectively.  He has held similar positions at Hong Kong Polytechnic University, Canberra University, the University of Warwick and The University of Surrey.  He held the position of senior fellow at the Institute of Defence and Strategic Studies at Nanyang University and the Civil Service College in Singapore during a sabbatical period in Nanyang. His paper with Boone on Leadership was the cover article for the Harvard Business Review in November 2007 and also won the Academy of Management aware for the best practitioner paper in the same year.  He has previously won a special award from the Academy for originality in his work on knowledge management. He is a editorial board member of several academic and practitioner journals in the field of knowledge management and is an Editor in Chief of E:CO.  In 2006 he was Director of the EPSRC (UK) research programme on emergence and in 2007 was appointed to an NSF (US) review panel on complexity science research. He previously worked for IBM where he was a Director of the Institution for Knowledge Management and founded the Cynefin Centre for Organisational Complexity; during that period he was selected by IBM as one of six on-demand thinkers for a world-wide advertising campaign. Prior to that he worked in a range of strategic and management roles in the service sector. His company Cognitive Edge exists to integrate academic thinking with practice in organisations throughout the world and operates on a network model working with Academics, Government, Commercial Organisations, NGOs and Independent Consultants.  He is also the main designer of the SenseMaker® software suite, originally developed in the field of counter terrorism and now being actively deployed in both Government and Industry to handle issues of impact measurement, customer/employee insight, narrative based knowledge management, strategic foresight and risk management. The Centre for Applied Complexity was established to look at whole of citizen engagement in government and is running active programmes in Wales and elsewhere in areas such as social inclusion, self-organising communities and nudge economics together with a broad range of programmes in health.  The Centre will establish Wales as a centre of excellence for the integration of academic and practitioner work in creating a science-based approach to understanding society.   Social Media and Website LinkedIn: https://uk.linkedin.com/in/dave-snowden-2a93b Twitter: @snowded Website: Cognitive Edge https://www.cognitive-edge.com/   Books/ Resources: Book: Cynefin - Weaving Sense-Making into the Fabric of Our World by Dave Snowden and Friends https://www.amazon.co.uk/Cynefin-Weaving-Sense-Making-Fabric-World/dp/1735379905 Book: Hope Without Optimism by Terry Eagleton https://www.amazon.co.uk/Hope-Without-Optimism-Terry-Eagleton/dp/0300248679/ Book: Theology of Hope by Jurgen Moltmann https://www.amazon.co.uk/Theology-Hope-Classics-Jurgen-Moltmann/dp/0334028787 Poem: ‘Mending Wall' by Robert Frost https://www.poetryfoundation.org/poems/44266/mending-wall Video: Dave Snowden on ‘Rewilding Agile' https://www.youtube.com/watch?v=QrgaPDqet4c Article reference to ‘Rewilding Agile' by Dave Snowden https://cynefin.io/index.php/User:Snowded Field Guide to Managing Complexity (and Chaos) In Times of Crisis https://cynefin.io/index.php/Field_guide_to_managing_complexity_(and_chaos)_in_times_of_crisis Field Guide to Managing Complexity (and Chaos) In Times of Crisis (2) https://ec.europa.eu/jrc/en/publication/managing-complexity-and-chaos-times-crisis-field-guide-decision-makers-inspired-cynefin-framework Cynefin Wiki https://cynefin.io/wiki/Main_Page   Interview Transcript Ula Ojiaku:  Dave, thank you for making the time for this conversation. I read in your, your latest book - the book, Cynefin: Weaving Sense Making into the Fabric of Our World, which was released, I believe, in celebration of the twenty first year of the framework. And you mentioned that in your childhood, you had multidisciplinary upbringing which involved lots of reading. Could you tell us a bit more about that? Dave Snowden:  I think it wasn't uncommon in those days. I mean, if you did… I mean, I did science A levels and mathematical A levels. But the assumption was you would read every novel that the academic English class were reading. In fact, it was just unimaginable (that) you wouldn't know the basics of history. So, if you couldn't survive that in the sixth form common room, and the basics of science were known by most of the arts people as well. So that that was common, right. And we had to debate every week anyway. So, every week, you went up to the front of the class and you were given a card, and you'd have the subject and which side you are on, and you had to speak for seven minutes without preparation. And we did that every week from the age of 11 to 18. And that was a wonderful discipline because it meant you read everything. But also, my mother was… both my parents were the first from working class communities to go to university. And they got there by scholarship or sheer hard work against the opposition of their families. My mother went to university in Germany just after the war, which was extremely brave of her -  you know, as a South Wales working class girl. So, you weren't allowed not to be educated, it was considered the unforgivable sin. Ula Ojiaku:   Wow. Did it mean that she had to learn German, because (she was) studying in Germany…? Dave Snowden:  She well, she got A levels in languages. So, she went to university to study German and she actually ended up as a German teacher, German and French. So, she had that sort of background. Yeah. Ula Ojiaku:  And was that what influenced you? Because you also mentioned in the book that you won a £60 prize? Dave Snowden:  Oh, no, that was just fun. So, my mum was very politically active. We're a South Wales labor. Well, I know if I can read but we were labor. And so, she was a local Councilor. She was always politically active. There's a picture of me on Bertrand Russell's knee and her as a baby on a CND march. So it was that sort of background. And she was campaigning for comprehensive education, and had a ferocious fight with Aiden Williams, I think, who was the Director of Education, it was really nasty. I mean, I got threatened on my 11 Plus, he got really nasty. And then so when (I was) in the sixth form, I won the prize in his memory, which caused endless amusement in the whole county. All right. I think I probably won it for that. But that was for contributions beyond academic. So, I was leading lots of stuff in the community and stuff like that. But I had £60. And the assumption was, you go and buy one massive book. And I didn't, I got Dad to drive me to Liverpool - went into the big bookshop there and just came out with I mean, books for two and six pence. So, you can imagine how many books I could get for £60. And I just took everything I could find on philosophy and history and introductory science and stuff like that and just consumed it. Ula Ojiaku:  Wow, it seemed like you already knew what you wanted even before winning the prize money, you seem to have had a wish list... Dave Snowden:  I mean, actually interesting, and the big things in the EU field guide on (managing) complexity which was just issued. You need to build…, You need to stop saying, ‘this is the problem, we will find the solution' to saying, ‘how do I build capability, that can solve problems we haven't yet anticipated?' And I think that's part of the problem in education. Because my children didn't have that benefit. They had a modular education. Yeah, we did a set of exams at 16 and a set of exams that 18 and between those periods, we could explore it (i.e. options) and we had to hold everything in our minds for those two periods, right? For my children, it was do a module, pass a test, get a mark, move on, forget it move on. So, it's very compartmentalized, yeah? And it's also quite instrumentalist. We, I think we were given an education as much in how to learn and have had to find things out. And the debating tradition was that; you didn't know what you're going to get hit with. So, you read everything, and you thought about it, and you learn to think on your feet. And I think that that sort of a broad switch, it started to happen in the 80s, along with a lot of other bad things in management. And this is when systems thinking started to dominate. And we moved to an engineering metaphor. And you can see it in cybernetics and everything else, it's an attempt to define everything as a machine. And of course, machines are designed for a purpose, whereas ecosystems evolve for resilience. And I think that's kind of like where I, my generation were and it's certainly what we're trying to bring back in now in sort of in terms of practice. Ula Ojiaku:  I have an engineering background and a computer science background. These days, I'm developing a newfound love for philosophy, psychology, law and, you know, intersect, how do all these concepts intersect? Because as human beings we're complex, we're not machines where you put the program in and you expect it to come out the same, you know, it's not going to be the same for every human being. What do you think about that? Dave Snowden:  Yeah. And I think, you know, we know more on this as well. So, we know the role of art in human evolution is being closely linked to innovation. So, art comes before language. So, abstraction allows you to make novel connections. So, if you focus entirely on STEM education, you're damaging the human capacity to innovate. And we're, you know, as creatures, we're curious. You know. And I mean, we got this whole concept of our aporia, which is key to connecting that, which is creating a state of deliberate confusion, or a state of paradox. And the essence of a paradox is you can't resolve it. So, you're forced to think differently. So, the famous case on this is the liar's paradox, alright? I mean, “I always lie”. That just means I lied. So, if that means I was telling the truth. So, you've got to think differently about the problem. I mean, you've seen those paradoxes do the same thing. So that, that deliberate act of creating confusion so people can see novelty is key. Yeah. Umm and if you don't find… finding ways to do that, so when we looked at it, we looked at linguistic aporia, aesthetic aporia and physical aporia. So, I got some of the… one of the defining moments of insight on Cynefin was looking at Caravaggio`s paintings in Naples. When I realized I've been looking for the idea of the liminality. And that was, and then it all came together, right? So those are the trigger points requiring a more composite way of learning. I think it's also multiculturalism, to be honest. I mean, I, when I left university, I worked on the World Council of Churches come, you know program to combat racism. Ula Ojiaku:  Yes, I'd like to know more about that. That's one of my questions… Dave Snowden:  My mother was a good atheist, but she made me read the Bible on the basis, I wouldn't understand European literature otherwise, and the penetration guys, I became a Catholic so… Now, I mean, that that was fascinating, because I mean, I worked on Aboriginal land rights in Northern Australia, for example. And that was when I saw an activist who was literally murdered in front of me by a security guard. And we went to the police. And they said, it's only an Abo. And I still remember having fights in Geneva, because South Africa was a tribal conflict with a racial overlay. I mean, Africa, and its Matabele Zulu, arrived in South Africa together and wiped out the native population. And if you don't understand that, you don't understand the Matabele betrayal. You don't understand what happened. It doesn't justify apartheid. And one of the reasons there was a partial reconciliation, is it actually was a tribal conflict. And the ritual actually managed that. Whereas in Australia, in comparison was actually genocide. Yeah, it wasn't prejudice, it was genocide. I mean, until 1970s, there, were still taking half -breed children forcibly away from their parents, inter-marrying them in homes, to breed them back to white. And those are, I think, yeah, a big market. I argued this in the UK, I said, one of the things we should actually have is bring back national service. I couldn't get the Labor Party to adopt it. I said, ‘A: Because it would undermine the Conservatives, because they're the ones who talk about that sort of stuff. But we should allow it to be overseas.' So, if you put two years into working in communities, which are poorer than yours, round about that 18 to 21-year-old bracket, then we'll pay for your education. If you don't, you'll pay fees. Because you proved you want to give to society. And that would have been… I think, it would have meant we'd have had a generation of graduates who understood the world because that was part of the objective. I mean, I did that I worked on worked in South Africa, on the banks of Zimbabwe on the audits of the refugee camps around that fight. And in Sao Paulo, in the slums, some of the work of priests. You can't come back from that and not be changed. And I think it's that key formative period, we need to give people. Ula Ojiaku:  True and like you said, at that age, you know, when you're young and impressionable, it helps with what broadening your worldview to know that the world is bigger than your father's … compound (backyard)… Dave Snowden:  That's the worst problem in Agile, because what, you've got a whole class of, mainly white males and misogynism in Agile is really bad. It's one of the worst areas for misogyny still left, right, in terms of where it works. Ula Ojiaku:  I'm happy you are the one saying it not me… Dave Snowden:  Well, no, I mean, it is it's quite appalling. And so, what you've actually got is, is largely a bunch of white male game players who spent their entire time on computers. Yeah, when you take and run seriously after puberty, and that's kind of like a dominant culture. And that's actually quite dangerous, because it lacks, it lacks cultural diversity, it lacks ethnic diversity, it lacks educational diversity. And I wrote an article for ITIL, recently, which has been published, which said, no engineers should be allowed out, without training in ethics. Because the implications of what software engineers do now are huge. And the problem we've got, and this is a really significant, it's a big data problem as well. And you see it with a behavioral economic economist and the nudge theory guys - all of whom grab these large-scale data manipulations is that they're amoral, they're not immoral, they're amoral. And that's actually always more scary. It's this sort of deep level instrumentalism about the numbers; the numbers tell me what I need to say. Ula Ojiaku:  And also, I mean, just building on what you've said, there are instances, for example, in artificial intelligence is really based on a sample set from a select group, and it doesn't necessarily recognize things that are called ‘outliers'. You know, other races… Dave Snowden:  I mean, I've worked in that in all my life now back 20, 25 years ago. John Poindexter and I were on a stage in a conference in Washington. This was sort of early days of our work on counter terrorism. And somebody asked about black box AI and I said, nobody's talking about the training data sets. And I've worked in AI from the early days, all right, and the training data sets matter and nobody bothered. They just assumed… and you get people publishing books which say correlation is causation, which is deeply worrying, right? And I think Google is starting to acknowledge that, but it's actually very late. And the biases which… we were looking at a software tool the other day, it said it can, it can predict 85% of future events around culture. Well, it can only do that by constraining how executive see culture, so it becomes a self-fulfilling prophecy. And then the recruitment algorithms will only recruit people who match that cultural expectation and outliers will be eliminated. There's an HBO film coming up shortly on Myers Briggs. Now, Myers Briggs is known to be a pseudo-science. It has no basis whatsoever in any clinical work, and even Jung denied it, even though it's meant to be based on his work. But it's beautiful for HR departments because it allows them to put people into little categories. And critically it abrogates, judgment, and that's what happened with systems thinking in the 80s 90s is everything became spreadsheets and algorithms. So, HR departments would produce… instead of managers making decisions based on judgment, HR departments would force them into profile curves, to allocate resources. Actually, if you had a high performing team who were punished, because the assumption was teams would not have more than… Ula Ojiaku:  Bell curve... Dave Snowden:  …10 percent high performance in it. All right. Ula Ojiaku:  Yeah. Dave Snowden:  And this sort of nonsense has been running in the 80s, 90s and it coincided with… three things came together. One was the popularization of systems thinking. And unfortunately, it got popularized around things like process reengineering and learning organization. So that was a hard end. And Sanghi's pious can the sort of the, the soft end of it, right? But both of them were highly directional. It was kind of like leaders decide everything follows. Yeah. And that coincided with the huge growth of computing - the ability to handle large volumes of information. And all of those sorts of things came together in this sort of perfect storm, and we lost a lot of humanity in the process. Ula Ojiaku:  Do you think there's hope for us to regain the humanity in the process? Because it seems like the tide is turning from, I mean, there is still an emphasis, in my view, on systems thinking, however, there is the growing realization that we have, you know, knowledge workers and people… Dave Snowden:  Coming to the end of its park cycle, I see that all right. I can see it with the amount of cybernetics fanboys, and they are all boys who jump on me every time I say something about complexity, right? So, I think they're feeling threatened. And the field guide is significant, because it's a government, you know, government can like publication around effectively taken an ecosystems approach, not a cybernetic approach. And there's a book published by a good friend of mine called Terry Eagleton, who's… I don't think he's written a bad book. And he's written about 30, or 40. I mean, the guy just produces his stuff. It's called “Hope without Optimism”. And I think, hope is… I mean, Moltman just also published an update of his Theology of Hope, which is worth reading, even if you're not religious. But hope is one of those key concepts, right, you should… to lose hope is a sin. But hope is not the same thing as optimism. In fact, pessimistic people who hope actually are probably the ones who make a difference, because they're not naive, right? And this is my objection to the likes of Sharma Ga Sengi, and the like, is they just gather people together to talk about how things should be. And of course, everything should be what, you know, white MIT, educated males think the world should be like. I mean, it's very culturally imperialist in that sort of sense. And then nobody changes because anybody can come together in the workshop and agree how things should be. It's when you make a difference in the field that it counts, you've got to create a micro difference. This is hyper localization, you got to create lots and lots of micro differences, which will stimulate the systems, the system will change. I think, three things that come together, one is COVID. The other is global warming. And the other is, and I prefer to call it the epistemic justice movement, though, that kind of like fits in with Black Lives Matter. But epistemic justice doesn't just affect people who are female or black. I mean, if you come to the UK and see the language about the Welsh and the Irish, or the jokes made about the Welsh in BBC, right? The way we use language can designate people in different ways and I think that's a big movement, though. And it's certainly something we develop software for. So, I think those three come together, and I think the old models aren't going to be sustainable. I mean, the cost is going to be terrible. I mean, the cost to COVID is already bad. And we're not getting this thing as long COVID, it's permanent COVID. And people need to start getting used to that. And I think that's, that's going to change things. So, for example, in the village I live in Wiltshire. Somebody's now opened an artisan bakery in their garage and it's brilliant. And everybody's popping around there twice a week and just buying the bread and having a chat on the way; socially-distanced with masks, of course. And talking of people, that sort of thing is happening a lot. COVID has forced people into local areas and forced people to realise the vulnerability of supply chains. So, you can see changes happening there. The whole Trump phenomenon, right, and the Boris murmuring in the UK is ongoing. It's just as bad as the Trump phenomenon. It's the institutionalization of corruption as a high level. Right? Those sorts of things trigger change, right? Not without cost, change never comes without cost, but it just needs enough… It needs local action, not international action. I think that's the key principle. To get a lot of people to accept things like the Paris Accord on climate change, and you've got to be prepared to make sacrifices. And it's too distant a time at the moment, it has to become a local issue for the international initiatives to actually work and we're seeing that now. I mean… Ula Ojiaku:  It sounds like, sorry to interrupt - it sounds like what you're saying is, for the local action, for change to happen, it has to start with us as individuals… Dave Snowden:  The disposition… No, not with individuals. That's actually very North American, the North European way of thinking right. The fundamental kind of basic identity structure of humans is actually clans, not individuals. Ula Ojiaku:  Clans... Dave Snowden:  Yeah. Extended families, clans; it's an ambiguous word. We actually evolved for those. And you need it at that level, because that's a high level of social interaction and social dependency. And it's like, for example, right? I'm dyslexic. Right? Yeah. If I don't see if, if the spelling checker doesn't pick up a spelling mistake, I won't see it. And I read a whole page at a time. I do not read it sentence by sentence. All right. And I can't understand why people haven't seen the connections I make, because they're obvious, right? Equally, there's a high degree of partial autism in the Agile community, because that goes with mathematical ability and thing, and that this so-called education deficiencies, and the attempt to define an ideal individual is a mistake, because we evolved to have these differences. Ula Ojiaku:  Yes. Dave Snowden:  Yeah. And the differences understood that the right level of interaction can change things. So, I think the unit is clan, right for extended family, or extended, extended interdependence. Ula Ojiaku:  Extended interdependence… Dave Snowden:  We're seeing that in the village. I mean, yeah, this is classic British atomistic knit, and none of our relatives live anywhere near us. But the independence in the village is increasing with COVID. And therefore, people are finding relationships and things they can do together. Now, once that builds to a critical mass, and it does actually happen exponentially, then bigger initiatives are possible. And this is some of the stuff we were hoping to do in the US shortly on post-election reconciliation. And the work we've been doing in Malmo, in refugees and elsewhere in the world, right, is you change the nature of localized interaction with national visibility, so that you can measure the dispositional state of the system. And then you can nudge the system when it's ready to change, because then the energy cost of change is low. But that requires real time feedback loops in distributed human sensor networks, which is a key issue in the field guide. And the key thing that comes back to your original question on AI, is, the internet at the moment is an unbuffered feedback loop. Yeah, where you don't know the source of the data, and you can't control the source of the data. And any network like that, and this is just apriori science factor, right will always become perverted. Ula Ojiaku:  And what do you mean by term apriori? Dave Snowden:  Oh, before the facts, you don't need to, we don't need to wait for evidence. It's like in an agile, you can look at something like SAFe® which case claims to scale agile and just look at it you say it's apriori wrong (to) a scale a complex system. So, it's wrong. All right. End of argument right. Now let's talk about the details, right. So yeah, so that's, you know, that's coming back. The hyper localization thing is absolutely key on that, right? And the same is true to be honest in software development. A lot of our work now is to understand the unarticulated needs of users. And then shift technology in to actually meet those unarticulated needs. And that requires a complex approach to architecture, in which people and technology are objects with defined interactions around scaffolding structures, so that applications can emerge in resilience, right? And that's actually how local communities evolve as well. So, we've now got the theoretical constructs and a lot of the practical methods to actually… And I've got a series of blog posts - which I've got to get back to writing - called Rewilding Agile. And rewilding isn't returning to the original state, it's restoring balance. So, if you increase the number of human actors as your primary sources, and I mean human actors, not as people sitting on (in front of) computer screens who can be faked or mimicked, yeah? … and entirely working on text, which is about 10%, of what we know, dangerous, it might become 80% of what we know and then you need to panic. Right? So, you know, by changing those interactions, increasing the human agency in the system, that's how you come to, that's how you deal with fake news. It's not by writing better algorithms, because then it becomes a war with the guys faking the news, and you're always gonna lose. Ula Ojiaku:  So, what do you consider yourself, a person of faith? Dave Snowden:  Yeah. Ula Ojiaku:  Why? Dave Snowden:  Oh, faith is like hope and charity. I mean, they're the great virtues… I didn't tell you I got into a lot in trouble in the 70s. Dave Snowden:  I wrote an essay that said Catholicism, Marxism and Hinduism were ontologically identical and should be combined and we're different from Protestantism and capitalism, which are also ontologically identical (and) it can be combined. Ula Ojiaku:  Is this available in the public domain? Dave Snowden:  I doubt it. I think it actually got me onto a heresy trial at one point, but that but I would still say that. Ula Ojiaku:  That's amazing. Can we then move to the framework that Cynefin framework, how did it evolve into what we know it as today? Dave Snowden:  I'll do a high-level summary, but I wrote it up at length in the book and I didn't know I was writing for the book. The book was a surprise that they put together for me. I thought that was just writing an extended blog post. It started when I was working in IBM is it originates from the work of Max Borrasso was my mentor for years who tragically died early. But he was looking at abstraction, codification and diffusion. We did a fair amount of work together, I took two of those aspects and started to look at informal and formal communities in IBM, and its innovation. And some of the early articles on Cynefin, certainly the early ones with the five domains come from that period. And at that time, we had access labels. Yeah. And then then complexity theory came into it. So, it shifted into being a complexity framework. And it stayed … The five domains were fairly constant for a fairly long period of time, they changed their names a bit. The central domain I knew was important, but didn't have as much prominence as it does now. And then I introduced liminality, partly driven by agile people, actually, because they could they couldn't get the concept there were dynamics and domains. So, they used to say things like, ‘look, Scrum is a dynamic. It's a way of shifting complex to complicated' and people say ‘no, the scrum guide said it's about complex.' And you think, ‘oh, God, Stacey has a lot to answer for' but… Ula Ojiaku: Who`s Stacey? Dave Snowden:  Ralph Stacey. So, he was the guy originally picked up by Ken when he wrote the Scrum Guide… Ula Ojiaku:  Right. Okay. Dave Snowden:  Stacey believes everything's complex, which is just wrong, right? So, either way, Cynefin evolved with the liminal aspects. And then the last resolution last year, which is… kind of completes Cynefin to be honest, there's some refinements… was when we realized that the central domain was confused, or operatic. And that was the point where you started. So, you didn't start by putting things into the domain, you started in the operatic. And then you moved aspects of things into the different domains. So that was really important. And it got picked up in Agile, ironically, by the XP community. So, I mean, I was in IT most of my life, I was one of the founders of the DSDM Consortium, and then moved sideways from that, and was working in counterterrorism and other areas, always you're working with technology, but not in the Agile movement. Cynefin is actually about the same age as Agile, it started at the same time. And the XP community in London invited me in, and I still think Agile would have been better if it had been built on XP, not Scrum. But it wouldn't have scaled with XP, I mean, without Scrum it would never have scaled it. And then it got picked up. And I think one of the reasons it got picked up over Stacey is, it said order is possible. It didn't say everything is complex. And virtually every Agile method I know of value actually focuses on making complex, complicated. Ula Ojiaku:  Yes. Dave Snowden:  And that's its power. What they're… what is insufficient of, and this is where we've been working is what I call pre-Scrum techniques. Techniques, which define what should go into that process. Right, because all of the Agile methods still tend to be a very strong manufacturing metaphor - manufacturing ideas. So, they assume somebody will tell them what they have to produce. And that actually is a bad way of thinking about IT. Technology needs to co-evolve. And users can't articulate what they want, because they don't know what technology can do. Ula Ojiaku:  True. But are you saying… because in Agile fundamentally, it's really about making sure there's alignment as well that people are working on the right thing per time, but you're not telling them how to do it? Dave Snowden:  Well, yes and no - all right. I mean, it depends what you're doing. I mean, some Agile processes, yes. But if you go through the sort of safe brain remain processes, very little variety within it, right? And self-organization happens within the context of a user executive and retrospectives. Right, so that's its power. And, but if you look at it, it took a really good technique called time-boxing, and it reduced it to a two-week sprint. Now, that's one aspect of time boxing. I mean, I've got a whole series of blog posts next week on this, because time boxing is a hugely valuable technique. It says there's minimal deliverable project, and maximum deliverable product and a minimal level of resource and a maximum level of resource. And the team commits to deliver on the date. Ula Ojiaku:  To accurate quality… to a quality standard. Dave Snowden:  Yeah, so basically, you know that the worst case, you'll get the minimum product at the maximum cost, but you know, you'll get it on that date. So, you can deal with it, alright. And that's another technique we've neglected. We're doing things which force high levels of mutation and requirements over 24 hours, before they get put into a Scrum process. Because if you just take what users want, you know, there's been insufficient co-evolution with the technology capability. And so, by the time you deliver it, the users will probably realize they should have asked for something different anyway. Ula Ojiaku:  So, does this tie in with the pre-Scrum techniques you mentioned earlier? If so, can you articulate that? Dave Snowden:  So, is to say different methods in different places. And that's again, my opposition to things like SAFe, to a lesser extent LeSS, and so on, right, is they try and put everything into one bloody big flow diagram. Yeah. And that's messy. All right? Well, it's a recipe, not a chef. What the chef does is they put different ingredients together in different combinations. So, there's modularity of knowledge, but it's not forced into a linear process. So, our work… and we just got an open space and open source and our methods deliberately, right, in terms of the way it works, is I can take Scrum, and I can reduce it to its lowest coherent components, like a sprint or retrospective. I can combine those components with components for another method. So, I can create Scrum as an assembly of components, I can take those components compared with other components. And that way, you get novelty. So, we're then developing components which sit before traditional stuff. Like for example, triple eight, right? This was an old DSDM method. So, you ran a JAD sessions and Scrum has forgotten about JAD. JAD is a really…  joint application design… is a really good set of techniques - they're all outstanding. You throw users together with coders for two days, and you force out some prototypes. Yeah, that latching on its own would, would transform agile, bringing that back in spades, right? We did is we do an eight-hour JAD session say, in London, and we pass it on to a team in Mumbai. But we don't tell them what the users ask for. They just get the prototype. And they can do whatever they want with it for eight hours. And then they hand it over to a team in San Francisco, who can do whatever they want with it in eight hours. And it comes back. And every time I've run this, the user said, ‘God, I wouldn't have thought of that, can I please, have it?' So, what you're doing is a limited life cycle -  you get the thing roughly defined, then you allow it to mutate without control, and then you look at the results and decide what you want to do. And that's an example of pre-scrum technique, that is a lot more economical than systems and analysts and user executives and storyboards. And all those sorts of things. Yeah. Ula Ojiaku:  Well, I see what you mean, because it seems like the, you know, the JAD - the joint application design technique allows for emergent design, and you shift the decision making closer to the people who are at the forefront. And to an extent my understanding of, you know, Scrum … I mean, some agile frameworks - that's also what they promote… Dave Snowden:  Oh, they don't really don't. alright. They picked up Design Thinking which is quite interesting at the moment. If you if you look at Agile and Design Thinking. They're both at the end of their life cycles. Ula Ojiaku:  Why do you say that? Dave Snowden:  Because they're being commodified. The way you know, something is coming to the end of its life cycle is when it becomes highly commodified. So, if you look at it, look at what they are doing the moment, the Double Diamond is now a series of courses with certificates. And I mean, Agile started with bloody certificates, which is why it's always been slightly diverse in the way it works. I mean, this idea that you go on a three-day course and get a certificate, you read some slides every year and pay some money and get another certificate is fundamentally corrupt. But most of the Agile business is built on it, right? I mean, I've got three sets of methods after my name. But they all came from yearlong or longer courses certified by university not from tearing apart a course. Yeah, or satisfying a peer group within a very narrow cultural or technical definition of competence. So, I think yeah, and you can see that with Design Thinking. So, it's expert ideation, expert ethnography. And it still falls into that way of doing things. Yeah. And you can see it, people that are obsessed with running workshops that they facilitate. And that's the problem. I mean, the work we're doing on citizen engagement is actually… has no bloody facilitators in it. As all the evidence is that the people who turn up are culturally biased about their representative based opinions. And the same is true if you want to look at unarticulated needs, you can't afford to have the systems analysts finding them because they see them from their perspective. And this is one of one science, right? You did not see what you do not expect to see. We know that, alright? So, you're not going to see outliers. And so, the minute you have an expert doing something, it's really good - where you know, the bounds of the expertise, cover all the possibilities, and it's really dangerous. Well, that's not the case. Ula Ojiaku:  So, could you tell me a bit more about the unfacilitated sessions you mentioned earlier? Dave Snowden:  They're definitely not sessions, so we didn't like what were triggers at moments. Ula Ojiaku:  Okay. Dave Snowden:  So, defining roles. So, for example, one of the things I would do and have done in IT, is put together, young, naive, recently graduated programmer with older experienced tester or software architect. So, somebody without any… Ula Ojiaku:  Prejudice or pre-conceived idea... Dave Snowden:  … preferably with a sort of grandparent age group between them as well. I call it, the grandparents syndrome - grandparents say things to their grandchildren they won't tell their children and vice versa. If you maximize the age gap, there's actually freer information flow because there's no threat in the process. And then we put together with users trained to talk to IT people. So, in a month's time, I'll publish that as a training course. So, training users to talk to IT people is more economical than trying to train IT people to understand users. Ula Ojiaku:  To wrap up then, based on what you said, you know, about Cynefin, and you know, the wonderful ideas behind Cynefin. How can leaders in organizations in any organization apply these and in how they make sense of the world and, you know, take decisions? Dave Snowden:  Well, if there's actually a sensible way forward now, so we've just published the field guide on managing complexity.  Ula Ojiaku:  Okay. Dave Snowden:  And that is actually, it's a sort of ‘Chef's guide'. It has four stages: assess, adapt, exert, transcend, and within that it has things you could do. So, it's not a list of qualities, it's a list of practical things you should go and do tomorrow, and those things we're building at the moment with a lot of partners, because we won't try and control this; this needs to be open. Here's an assessment process that people will go through to decide where they are. So that's going to be available next week on our website. Ula Ojiaku:  Oh, fantastic! Dave Snowden:  For the initial registration.  Other than that, and there's a whole body of stuff on how to use Cynefin. And as I said, we just open source on the methods. So, the Wiki is open source. These… from my point of view, we're now at the stage where the market is going to expand very quickly. And to be honest, I, you know, I've always said traditionally use cash waiver as an example of this. The reason that Agile scaled around Scrum is he didn't make it an elite activity, which XP was. I love the XP guys, but they can't communicate with ordinary mortals. Yeah. It takes you about 10 minutes to tune into the main point, and even you know the field, right. And he (Jeff Sutherland) made the Scrum Guide open source. And that way it's great, right. And I think that that's something which people just don't get strategic with. They, in early stages, you should keep things behind firewalls. When the market is ready to expand, you take the firewalls away fast. Because I mean, getting behind firewalls initially to maintain coherence so they don't get diluted too quickly, or what I call “hawks being made into pigeons”. Yeah. But the minute the market is starting to expand, that probably means you've defined it so you release the firewall so the ideas spread very quickly, and you accept the degree of diversity on it. So that's the reason we put the Wiki. Ula Ojiaku:  Right. So, are there any books that you would recommend, for anyone who wants to learn more about what you've talked about so far. Dave Snowden:  You would normally produce the theory book, then the field book, but we did it the other way around. So, Mary and I are working on three to five books, which will back up the Field Guide. Ula Ojiaku:  Is it Mary Boone? Dave Snowden:  Mary Boone. She knows how to write to the American managers, which I don't, right… without losing integrity. So that's coming, right. If you go onto the website, I've listed all the books I read. I don't think… there are some very, very good books around complexity, but they're deeply specialized, they're academic. Gerard's book is just absolutely brilliant but it's difficult to understand if you don't have a philosophy degree. And there are some awfully tripe books around complexity - nearly all of the popular books I've seen, I wouldn't recommend. Yeah. Small Groups of Complex Adaptive Systems is probably quite a good one that was published about 20 years ago. Yeah, but that we got a book list on the website. So, I would look at that. Ula Ojiaku:  Okay. Thank you so much for that. Do you have any ask of the audience and how can they get to you? Dave Snowden:  We've open-sourced the Wiki, you know, to create a critical mass, I was really pleased we have 200 people volunteered to help populate it. So, we get the all the methods in the field guide them. And they're actively working at that at the moment, right, and on a call with them later. And to be honest, I've done 18-hour days, the last two weeks, but 8 hours of each of those days has been talking to the methods with a group of people Academy 5, that's actually given me a lot of energy, because it's huge. So, get involved, I think it's the best way… you best understand complexity by getting the principles and then practicing it. And the key thing I'll leave us with is the metaphor. I mentioned it a few times - a recipe book user has a recipe, and they follow it. And if they don't have the right ingredients, and if they don't have the right equipment, they can't operate. Or they say it's not ‘true Agile'. A chef understands the theory of cooking and has got served in apprenticeship. So, their fingers know how to do things. And that's… we need… a downside.. more chefs, which is the combination of theory and practice. And the word empirical is hugely corrupted in the Agile movement. You know, basically saying, ‘this worked for me' or ‘it worked for me the last three times' is the most dangerous way of moving forward. Ula Ojiaku:  Because things change and what worked yesterday might not work Dave Snowden:  And you won't be aware of what worked or didn't work and so on. Ula Ojiaku:  And there's some bias in that. Wouldn't you say? Dave Snowden:  We've got an attentional blindness if you've got Ula Ojiaku:  Great. And Dave, where can people find you? Are you on social media? Dave Snowden:  Cognitive. Yeah, social media is @snowded. Yeah. LinkedIn, Facebook and Twitter. Two websites – the Cognitive Edge website, which is where I blog, and there's a new Cynefin Center website now, which is a not-for-profit arm. Ula Ojiaku:  Okay. All these would be in the show notes. Thank you so much for your time, Dave. It's been a pleasure speaking with you. Dave Snowden:  Okay. Thanks a lot.

This week, Dr. Scott Sigman sits down with Sarah Mayes, Ph.D., Chief Scientific Officer and Co-founder of Alafair Biosciences, and Dr. Eric Giza, Professor of Orthopaedic Surgery, Chief, Foot & Ankle Service, Co-Director, UC Davis/Reno Foot & Ankle Fellowship Head Team Physician, Sacramento Republic FC, UC Davis Department of Orthopaedic Surgery,  to discuss the journey behind VersaWrap Hydrogel Sheet. From its humble beginnings in a university lab to becoming an innovative solution for tendon and nerve protection, VersaWrap is redefining soft tissue healing. Sarah shares the entrepreneurial hurdles of bringing a medical device to market, while Dr. Giza provides a surgeon's perspective on how this cutting-edge product is impacting patient outcomes.

In Episode 34, join our founder, Danné Montague-King, alongside DMK's Chief Scientific Officer, Dr. Jayant Lokhande, as they dive deep into "Understanding Pigmentation in Melanated Skin."This episode is packed with essential information on:✅ Demystifying melanin—its science, roles, and unique characteristics in melanated skin.✅ Addressing and correcting common skincare myths surrounding deeper skin tones.✅ Detailed breakdown of pigmentation conditions like melasma and post-inflammatory hyperpigmentation (PIH).✅ DMK's revolutionary bio-inspired approach for safely treating pigmentation concerns.✅ Actionable, culturally-sensitive practices every skincare professional should incorporate.Instagram - Facebook - TikTok - Twitterwww.dannemking.com

Dr. Keshav K. Singh is the Joy and Bill Harbert Endowed Chair and Professor of Genetics, Dermatology and Pathology at the University of Alabama at Birmingham. He is also the founding Editor-in-Chief of the Mitochondrion Journal. In addition, Keshav is the founder and Chief Scientific Officer of the company Yuva Biosciences. Research in Keshav's lab focuses on how to reverse aging and diseases like cancer that are associated with aging. Mitochondria are relevant for all of the hallmarks of aging, including things like changes in epigenetic regulation, genomic instability, and communication problems between cells. He is working to better understand the intricacies of how mitochondria work and how they can be targeted or leveraged to improve health. Outside of work, Keshav enjoys flying kites on the beach, traveling, and painting. In particular, he gets creative painting all different kinds of mitochondria, and this is a great outlet for him when experiments aren't working in the lab. Keshav began his studies in India, earning his Bachelor of Science degree in microbiology from Rohilkhand University and his Master of Science from G.B. Pant University of Agriculture and Technology. Next, he moved to Australia and was awarded his Ph.D. in Marine Biology from the University of Wollongong. Keshav then conducted postdoctoral research at Harvard University before joining the faculty at Johns Hopkins University School of Medicine. He later moved to the Roswell Park Comprehensive Cancer Center and served as Distinguished Professor of Oncology. Next, he joined the faculty at the University of Alabama at Birmingham where he is today. He is a Fellow of the Royal Society of Medicine and a member of Sigma Xi (The Scientific Research Honor Society). He has been recognized as one of the Innovation Heroes by Newsweek, and Yuva Biosciences was the recipient of the "Company of the Year - Innovation and Excellence into Mitochondrial Science" award at the Indian Icon Awards. In our interview, Keshav shares more about his life and science.

EP 205: Catharine Arnston, founder and Chief Scientific Officer of ENERGYbits, is back for another fascinating conversation—this time focused on women's health, hormones, and the power of algae. We dive into how spirulina and chlorella support mitochondrial function, balance hormones, and deliver potent antioxidant benefits, all grounded in decades of research. Catharine's passion for algae began when her sister fell ill, sparking a journey that led to the creation of ENERGYbits. Her deep knowledge and infectious enthusiasm make this a must-listen for anyone curious about how a simple, sustainable superfood can make a big impact. Check Out ENERGYbits | Click Here & use code DRTYNA for 20% off Topics Discussed:  How does algae support women's hormonal health and balance? What are the benefits of spirulina and chlorella for mitochondrial function? Can algae help with symptoms of perimenopause and menopause? Why is algae considered one of the most nutrient-dense superfoods? How do antioxidants in algae improve overall health and energy levels? On This Episode We Cover:  00:00:00 - Introduction  00:02:20 - Manufacturing process  00:04:22 - Different types of algae  00:06:37 - Manufacturing process 00:12:49 - Vegan collagen  00:14:43 - Mitochondrial health & estrogen  00:19:32 - Perimenopause 00:26:11 - Women's aging & hormone health  00:28:49 - Estrogen levels  00:34:55 - Dr. Tyna's experience with ENERGYbits  00:38:04 - Carnivore diet & chlorophyll  00:40:50 - Red light  00:45:43 - B Vitamins & decision fatigue  00:47:31 - Constipation  00:49:53 - Aging and finding joy  00:56:04 - Testimonials  Further Listening:  EP. 139: Algae 101 | Catharine Arnston of Energy Bits Hormones Playlist Sponsored By: ENERGYbits | Click Here & use code DRTYNA for 20% off Disclaimer: Information provided in this podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional, or any information contained on or in any product. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal or other supplement, or using any treatment for a health problem. Information provided in this blog/podcast and the use of any products or services related to this podcast by you does not create a doctor-patient relationship between you and Dr. Tyna Moore. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease.

Peter A McCullough, MD, MPH, Chief Scientific Officer, TWC. twc.health/GRUBER. Promo Code GRUBER Saves 10%

The amount of time children and adolescents spend with a screen is absolutely stunning. Lots of people, including parents, health leaders, educators, elected leaders from both parties I might mention, and even children themselves, are highly concerned and are discussing what might be done about all this. I'm delighted to begin this series of podcasts on children and screen time. Today we're welcoming two very special guests who can talk about this topic in general, and especially about what's being done to protect children and adolescents. Several podcasts will follow this one that deal with food and nutrition in particular. Our first guest, Kris Perry, is Executive Director of Children and Screens, an organization devoted to protecting children. In the digital world by addressing media's impact on child development, communicating state-of-the-art information, and working with policymakers. Prior to joining children in Screens, Kris was senior advisor of the Governor of California and Deputy Secretary of the California Health and Human Services Agency. Our other guest, Dr. Dimitri Christakis is a professor of pediatrics at the University of Washington School of Medicine, and director of the Center for Child Health Behavior and Development at Seattle Children's. He's also editor-in-chief of JAMA Pediatrics and both Chief Scientific Officer and Chair of the Scientific Advisory Board of Children and Screens. He's also the co-editor of a new book that I'm very excited to discuss. Interview Summary Download The Handbook of Children and Screens: https://link.springer.com/book/10.1007/978-3-031-69362-5 Kris, let's start with you. Could you set the stage and give us some sense of how much time children spend in front of screens, children and adolescents, and what devices are being used and what kind of trends are you seeing? Yes, I'd be happy to. I had better news for your listeners, but as you might imagine, since the advent of the smartphone and social media, the youth digital media use has been increasing each year. Especially as children get older and have increasing demands on their time to use screens. But let's just start at the beginning of the lifespan and talk about kids under the age of two who shockingly are spending as much as two hours a day on screens. Most spend about 50 minutes, but there's a significant chunk spending up to two hours. And that rises to three or three to five hours in childhood. And eventually in adolescence, approximately eight and a half hours a day our adolescents are spending online. Also wanted to talk a little bit about middle childhood children, six to 12 years of age. 70% of them already have a social media account, and we all know social media wasn't designed for children. And there are restrictions on children under 13 using them, and yet children six to 12 most have an account already. Over half of four-year-olds have a tablet and two thirds of children have their own device by the age of eight; and 90% of teens. This probably won't be surprising, and yet we should really think about what this means; that 90% of teens are using YouTube, 60% are on TikTok and Instagram, and 55% use Snapchat. I'll stop by ending on a really alarming statistic. Oh my, there's more? There's more. I know it! I told you. I'll be the bearer of bad news so that we can talk about solutions later. But, children are checking their devices as often as 300 times per day. 300 times. 300 times per day, and we're talking about screen time right now. And we know that when you're using time to be on screens, you are not doing something else. And we know that childhood is full of challenges and skill building and mastery that requires repetition and tenacity and grit and effort. And the more children are on their screens, whether it's social media or other entertainment, they're not doing one of these other critical child development tasks. That's pretty amazing. And the fact that the older kids are spending more time on before a screen than they are in school is pretty alarming. And the younger, the really youngest kids, that's especially alarming. So, Dimitri, why should we fret about this? And I realize that fret is kind of a mild word here. Maybe all I'll panic would be better. But what are some of the major concerns? Well, I don't think panic is ever the right reaction, but the numbers Kris conveyed, you know, I think do paint a, let's say, concerning story. You know, the simple reality is that there's only so much time in a day. And if you think about it, teenagers in particular should sleep for eight to 10 hours a day at a minimum. They really should be in school six and a half, seven hours a day. And then when you add the numbers, Kris conveyed, you realize that something's giving because there isn't enough time left to spend eight and a half hours a day. The two things at a minimum that are giving are sleep. Kids are losing sleep to be on screens. And I'm sorry to say that they're losing school while they're on screens. We just published a paper that used passive sensing to see where and when children are on their screens. And found that the typical child in the United States spends an hour and a half during the school day on their device. And it's not, before any of your guests ask, on Wikipedia or Encyclopedia Britannica. It's on the usual suspects of social media, TikTok, etc. So, you know, we talk about displacement, and I think it's pretty obvious what's being displaced during school hours. Its time focused on learning if it's in the classroom, and time focused on being authentically present in real time and space if it's during recess. School hours are precious in that way, and I think it is concerning that they're spending that much time in school. And I told you the median. Of course, some kids are above that, a significant half of them are above it. And at the high end, they're spending 30 to 40% of school time on screens. Now, some schools have enacted policies. They don't typically enforce them very well. One of the things that drives me nuts, Kelly, is that as an academic, you know we love to argue amongst ourselves and hem and haw. And this issue about whether or not there's such a phenomenon as digital addiction is still being hotly debated. Honestly, the only behavioral addiction that's being seriously considered at this point is gaming disorder. The DSM-5 didn't consider gaming, considered it, but didn't include, it said it needed further study in 2013. In 2022, the WHO did include gaming disorder as an ICD-11 diagnosis. But just as further evidence how slow science is compared to technology., I mean gaming, while it's still an entity, represents a small fraction of most people's screen time. And the numbers that Kris conveyed, a small fraction of that for some on average was gaming. For some people, it's their screen use of choice, but for many, it's social media. YouTube, although I consider YouTube to be a social media, etc. And at the high end when you hear the numbers Kris conveyed in my mind that's a behavioral addiction any way you define it. Well, and if you think about things that we all agree are addictive, like nicotine and alcohol and heroin, people aren't doing it 300 times a day. So it's really pretty remarkable. And that's exactly right. One of the salient criteria for those addictions is that it's interfering with activities of daily living. Well, you can't be on a screen for nine hours a day when you're supposed to be asleep for 10 and at school for six without interfering with activities of day. The math isn't there. And things like being physically active and going out and playing. That's right. It doesn't add up. So, you don't need the DSM-5. You don't need a psychiatrist. You need a mathematician to tell you that there's too much time on this thing. Alright, so Kris, talk to us if you will, about the Children and Screens organization. I have a lot of respect for the organization and its work. Tell us how it got started and what its objectives are. Well, it's so great to be on this show with you and get to see you in your day job, Kelly. Because you've been an advisor, like Dimitri, to the institute almost since its inception, which is in 2013. As you know, our founder, Dr. Pamela Hurst-Della Pietra, really became concerned as a parent about the way digital media was impacting her children and sought out some answers. Well, what does this mean? Why is this happening? What should I do? And found out that this, of course, is 2013, this is a long time ago. There wasn't that much research yet. And it was multidisciplinary. In other words, there might be a study among neuroscientists or developmental psychologists, even ophthalmologists. But there really hadn't been, yet, a concerted effort to bring these different disciplines and the research together to try to answer some of these hard questions about the impact on kids. And lo and behold, here we are, almost 13 years since the advent of the smartphone and social media. And there is an astounding amount of research across disciplines. So, what we do at the institute is we try to translate it as fast as we can and make it actionable for parents, providers, and policy makers. And we do that through our Ask the Experts webinar series where we bring the experts themselves directly to our audience to talk about these impacts and answer questions. We also create printables, you might say, like tip sheets and Research at a Glance Digest, and newsletters and FAQs and we've upgraded our website to make it very navigable for parents of kids of all ages. I even started my own podcast this year, which has been really fun. Dimitri was my first guest, so it's great to see him here. And we have convenings. We're having our third Digital Media Developing Mind Scientific Congress this summer where the experts come together in person to discuss issues. And we really try to focus them on advancing research and supporting it, translating it, and positioning the issue as a policy priority. We'll be in Washington, DC where we know lawmakers are grappling with the impact of digital media on child development, how to make online, products safer for kids and protect their data. The Institute is in the middle of all of this, trying to facilitate more discussion, more results and more support for parents primarily. Kris, a couple of things occur to me. One is that the breadth of work you do is really very impressive because you're not only having very hands-on kind of in the real world ex advice for parents on how to navigate this world, but you have advice for and helpful resources for policy makers and for researchers and people. It's really quite an impressive breadth of work. The other thing that occurred to me is that I don't think you and I would have any podcast career at all if it hadn't been for Dimitri helping us out. So thanks Dimitri. Yeah. So, let me ask you, Dimitri, so I know that both you and Kris are committed to an evidence-based approach to making policy. Yeah. But technology advances way more quickly than scientists can evaluate it. Much less come up with policies to deal with it. And by the time research gets funded, completed, published, you're on to eight new levels of technology. So how does one handle this fundamental problem of pace? It's a really good question. I mean, I can tell you that we should at a minimum learn from the mistakes we've made in the past. And, you know, one of the most critical, frankly, that most people don't really understand is that we talk about the age at which children get social media accounts in this country. Kris pointed out that actually pre-teens routinely have social media accounts. Social media companies do very little to age gate. They're trying to do more now, but even the age at which we've accepted it is being normative is 13. Few people know where that comes from. That doesn't come from talking to pediatricians, psychologists, parents about what age is the appropriate age. It comes entirely from COPPA (Children's Online Privacy Protection Act), which basically was the original privacy act that said that before the age of 13, companies could not collect data from children. So, because these companies were interested in collecting data, they set the age at 13 so as to not have any constraints on the data they collected. Well, that's not even common sense-based policy, let alone evidence-based policy. And it's never been revisited since. It's very troubling to me. And as things move forward, I think we have to learn from those mistakes. Medicine has a maxim which is do no harm. We use that phrase a lot and I think it's a good one in this case. I think it's a particularly good one as we see the new technologies emerging around artificial intelligence. And you know, again, like any new technology, it has incredible upside. We made the mistake and we're still paying for it, about not appreciating the downsides of social network sites, and frankly, the internet in general. And I would hope we put guardrails in place now. And if you will apply the same standard we apply to other non-technology based products. You can't introduce a new pharmaceutical to anybody, let alone to children, until you show it's safe and effective. You can't bring toys to the world that are dangerous. Why do we have more safety precautions around toys than we do around websites for children? You know, a lot of it involves changing defaults, doesn't it? Because if the default is that government or somebody out there has to prove that something is harmful before it gets taken away. That changes everything then if you began at a different point where these companies have to prove that these things are safe. Correct. Or they're permitted. Then the companies would find workarounds and they would play games with that too, but at least that would help some. Well, it would help some. And at least we'd be philosophically in the right place. By the way, Kris didn't say it, so I'll say it. You know, the mission of Children and Screens, lest we sound like Luddites here, is not get kids away from technology. Take away their smartphones. We all recognize that technology is here to stay. I think all of us appreciate the incredible upside that it brings to children's lives. The mission of Children and Screens is to help children lead healthy lives in a digital world. And part of the reason she and I often talk about the concerns we have is because the pros make the case for themselves. I mean, you know, no one needs to come here and tell you how amazing it is that you could Google something or that you could get somewhere with GPS. I mean, we know it's amazing and we all rely on it. And none of us are ever talking about getting rid of that stuff. That makes good sense. It's like, you know, children benefit from the fact that they can get around with their parents in the automobile. But you want to have car seats in there to protect them. Exactly. And that's exactly right. There needs to be assurances of safety and they're none. I mean, they're really virtually none. The age getting is a joke. And even if we accept it as effective, the age set of 13 is too young, in my opinion. We started this conversation talking about these medias being addictive, I believe they're addictive. There are legitimate academics that will debate me on that, and I'm happy to join that debate. But as I said before, it's a tough argument to win when people spending upwards of 10 to 16 hours a day doing it. I don't know what you call that besides addictive. We can argue about what percentage are doing that, but nevertheless, once you accept something as addictive, for other addictive things we immediately age gate it above 18 or 21, right? Mm-hmm. We don't believe that the teenagers have the ability to regulate their alcohol or tobacco or gambling, all of which we accept are addictive. In fact, in the case of alcohol, we raised the age from 18 to 21 because we thought even 18-year-olds weren't able to do it. And yet somehow for this behavior, we think of it as just so different that it doesn't require greater cognitive capacity. And I don't believe that. Yeah, very good point. Kris, let me ask you a question about how you and your colleagues at Children and Screens set priorities because there are a lot of things that one could potentially worry about as outcomes. There's violence that kids see on social media. There's cognitive and brain development, social developments, social interactions, and bullying. Mental health, body image, diet, all these things are out there. How do you decide what to work on? Well, we try to work on all of it. And in fact, we've built up a fair amount of expertise and resources around almost 25 different topics. And we also understand that, you know, childhood is a long period of time. Birth to 18, birth to 21, birth to 25, depending on who you talk to. So, we're able to take those 25 topics and also provide deeper, you might say, resources that address the different stages of development. We're really trying to do as much as we can. What's been interesting over these last few years is trying to figure out when to be reactive, when to be proactive. And by being proactive, we go out looking for the research, translating it, digesting it, and creating materials with it that we think are really accessible and actionable. At the same time, as Dimitri points out, there are policy windows and there are opportunities that present themselves that you have to react to. If you just only talk about what you want to talk about to each other you're missing some of these external opportunities to inform policy and policy makers. Help influence the way that parents and providers are talking about the issue. Framing it in such a way that engages youth and makes them want what we want for them. We're really excited by increasing opportunities to partner in coalitions with others that care about kids and teachers and nurses and doctors. But we also are speaking directly to leaders in states and school districts at the federal level, at the local level. You would be, I'm sure, not surprised to hear that we are contacted every day by groups that support parents and families. Asking for resources, asking for support, because they're seeing the impact now over many years on their children, their development. Their academic ability. Their cognitive and analytical ability. Their social emotional ability. Their ability to pay attention to tasks that we all know are critical in building that foundation for essentially, you know, future success. The Institute is being pulled in many directions. Ee try really hard to be strategic about what are people asking us for? What does the research say and how can we get that to them as quickly as possible? Dimitri - Can I add to that? You know, I want to emphasize that the concern around the effects of screen use on children's lives is shared by parents on both sides of the aisle. 75% of parents are concerned about the impact of screens on their children's lives. 35% of teenagers are concerned about their dependents on screens and that it has a negative effect on their lives. Actually by some studies, some surveys, even more than 35 to 50% of teenagers are concerned. And both sides of the political aisle agree in large part of this. And Kris and Kelly, you guys are the policy wonks, you can speak more to that. So it's a serious indictment on us as grownups and as a society that we have not done more to deliver on this issue. Why? When there's bipartisan agreement amongst many policymakers. This is not a political [00:22:00] issue to speak of and there is widespread concern on the part of parents and even teenagers. Why is nothing happening? Well, one has to look no further than where the money is. And that's a problem. I mean, that's a serious indictment on our political system when we can't deliver something that is needed and basically wanted by everybody but the industry itself. We'll come back and talk in a few moments about the policy issues and where industry gets involved here. But let me take just a bit of a detour from that and talk about the book that I mentioned earlier, because I think it's such a valuable resource. Now, when I mention the name of this book I'm urging our listeners to write this down or to remember it because you can get the book at no cost. And I'll come back, Kris, and explain what made that possible and why the decision was to make this an open access book. But Dimitri, let's begin with you. So you, along with Lauren Hale, edited this book that's entitled, The Handbook of Children and Screens: Digital Media Development and Wellbeing From Birth Through Adolescence. I think it's an extraordinary piece of work, but tell, tell us about the book.  It was an extraordinary undertaking. There's I think 178 or 180 authors. Literally, it's a who's who of experts in children and media research in all disciplines. It represents pediatrics, psychiatry, psychology, communications experts, demography, lawyers, neuroscientists. I don't know who I'm forgetting. Every single discipline is represented. Leading scientists in all of those areas. Virtually every topic that someone might be of interest to people. And we deliberately made the chapters short and easily accessible. So, it is, I think, a great resource for the constituents we serve. For teachers, for parents, for researchers, for policymakers. And it is free. The hardest part of it, to be honest, as an editor, was getting peer reviewers because unfortunately, every expert was conflicted since they all had an article in it. But it was a long time coming. And again, this was really the brainchild of Pam (Pamela Hurst-Della Pietra) and we're grateful to have brought it along. So, you go all the way from the neuroscience, how children's brains are reacting to this, all the way out there into the public policy and legal arena about what can be done about it. And then kind of everything in between. It's remarkable how much the book covers. It's almost a thousand pages. I mean, it is a tome to be sure. And don't forget to mention, Dimitri, we aren't even two months post publication, and we have 1.6 million views of the document, despite its gargantuan size. I think that is really a tribute to experts like you and others that have really studied this issue and can speak directly to its impacts. It's been great to see the success so far. You know, not a small number of those views is from me logging on. And then a million from me and then we got there. So, it is free because it's online and you can download it. You can also order a hard copy for I think, $60, but I'm not sure why you would do that if you can download it for free. But it's up to you. So, Kris, it's unusual for a book like this to be made open access and free to the general public. What made that possible and why was that so important? We want the maximum number of people to use it and treat it like the premier resource that it is. And the only way you can really do that is to fund it to be open access and find a publisher that does open access publishing, which we did with Springer. I mean, most journal articles are behind a paywall and publishers do require you to purchase either a subscription or the document itself to download it or order it. And we just really wanted maximum access. So, we funded it to be published in that way. And I think honestly, it helped us even sort of create it in the first place. People want to be a part of something that has that level of access and is available so widely. So, I think it was a kind of mutually beneficial. It gets more people to read it, but it got more people to write for it too, I think. Right, Dimitri? Dimitri - I agree. I mean, you know, the numbers 1.6 million are extraordinary. I mean, Kelly, you've been internal editor. I mean, as a editor of JAMA Pediatrics, if an article gets 70,000 views, it's in our top 1%, you know, 200,000 views is 0.01%. 1.6 million in growing is really extraordinary. And that's about the number of people that read my articles. 1.6. And of course, they're not all scientists. I mean, many of them are parents and maybe are policy makers, but that's Kris's point, you know. The moment anyone hits a paywall, even if it's a dollar or two, they're going to walk away. It's great to see it get so much traction. Alright, so again, for our listeners, the title of the book is The Handbook of Children and Screens. And it's really a terrific resource. Alright, so let's turn our attention to a really important matter. And we've sort of touched on this, but who's in charge of protecting our children? You know, Dimitri at the end of the day help survey this landscape for us. I mean, is it congress, is it the administrative branch of government? What role do the courts play? Are there legal actors taking meaningful action? What's being done does it come anywhere near, meeting the need. Tell us about what that landscape is like? Well, there isn't adequate protections for children. And we talked a little bit about that earlier. There's been an enormous loophole, unfortunately, created by Congress when they added the Section 230 to the Communications Decency Act in 1996. And that was put in place essentially to provide protections for internet companies. And it basically said that they should be treated like bookstores and not publishers. That they weren't responsible for content they were just conveying it. And what that means, in effect, was that the companies had sort of carte blanche to do whatever they want. And they've used that very effectively, legally, to argue that any restriction, any culpability on their part, is protected by that Act. That they're exonified for any ill that occurs as a result of their product. The only exception that's been made of it, to date, was around sex trafficking on back page, if anyone remembers that. But other than that, social media sites and internet sites in general have been able to say that they're not liable for anything that's done. And I think that was a huge mistake that was made. It needs to be rectified. It's being challenged in the courts presently. My own belief is that, and I'm not speaking as a lawyer, is that when that law was passed, it was under the assumption as I said, that they were just conveying information. No one at the time foresaw the development of algorithms that would feed the information. It's really not a bookstore when you are making recommendations. Once you start recommending things, I think you're no longer merely a purveyor of product. You're actually pushing it. So, Kris, tell us about the Children and Screens and the role the organization plays in this space. And how do you deal with policy and is it possible to be bipartisan? Yeah, I mean, it's essential. There's no way to get anything done, anywhere on these policy matters at a population level without working in a bipartisan or non-partisan manner, which is what we've always done. And it's easy to do that when you're following the science, not ideology. And you're putting the science first and you're creating resources and tools and support for those mostly staffers, honestly, that are trying to help their bosses get smarter and better at talking about these issues as they evolve and become more complicated over time. It takes more effort to staff a lawmaker on this front. And they're very anxious to learn and understand because they're meeting with parents of children who have been harmed. Or frankly didn't even survive their childhood because of the social media platform. There's great urgency on the part of policymakers. We've heard everything from school phone bans to outright social media bans proposed as policies. And one thing I like to come back to is it's one thing to want to take action and make your best guess at what would have the best impact. But it's another thing to study whether or not that policy actually achieved its result. And it's a part of this that by staying bipartisan, nonpartisan allows us to say, 'Hey lawmaker, if you're able to get that to happen, we'd really like to come in and help study whether or not your idea actually achieves the results that you wanted, or if it needs to be adjusted or amended over time.' Fantastic. That's so important to be doing that work, and I'm delighted the organization is doing it. Let me ask a question here. If you think about some of the areas of public health that I've been following, like tobacco, for example. Opioids more recently. Vaping products. And in the case of my own particular work food policy. The administrative legislative branches of government have been almost completely ineffective. If I think about food policy over the years, relatively little has been accomplished. Even though lots of people have worked really hard on it. Same thing happened with tobacco for many years. Opioids, same thing.  And it's until you get the third branch of government involved, the judiciary, and you start suing the actors who were causing the harm do you get much action. Not only do the lawsuits seem to have an effect, but they soften the ground for legislative things that then can occur because public opinion has changed. And then those things help make a difference as well. What do you think about that kind of issue in this space?  I think you're exactly right. I mean, I think the failure of our legislative branch to enact policy leaves us with very few options at this point anyway, except to try to pursue it through the judiciary. There are challenges there. First and foremost, it's a big and well-funded industry, not unlike tobacco or big food, as you mentioned and there's this Section 230 that's given them kind of blanket immunity to date. But there are many, many very large pending cases in several jurisdictions brought by individuals, brought by school districts, brought by states. And those, at least provisionally have gotten further than prior cases have with which have been thrown out based on Section 230. So, we'll see what happens with that litigation. But right now, my guess is it's the best chance we have to set some guardrails. And I think there are plenty of guardrails that could be set. Everything that these companies have done to make their products addictive can be undone. Can be made protective. The tobacco company deliberately designed their products to be addictive. While they tried to make the claims that they were less addictive, you know. They made light cigarettes that had holes in the filter so that it would diffuse the carbon and nicotine, but people quickly learned they could cover those up with their fingers and think they were smoking light cigarettes, and smoke more of them. There's a lot of things that can be done in this space to undesign the problematic nature of the products. And quite apart from the financial settlements, which will get companies attention, I hope that that's part of any settlement if it gets that far. It'll be interesting to see where those go. And, also historically, one important part of these lawsuits is what gets turned up in discovery. And what sort of intent the companies have and how much do they know about harms. And how much do they know about addiction and things like that. And how they might have proceeded in the face of that information that then doesn't get disclosed to the public. In any event, we'll see where that goes. Dimitri, what about the argument that responsibility resides with parents. It's up to parents to protect their kids from this, and government doesn't need to be involved. I've never understood that argument. I mean parents obviously are children's most important safeguard, but as a society, we enact policies and laws to assist parents in that. I mean to me, if I made the argument, well, why, why do we have minimum ages of drinking. It's parents' job to make sure their kids don't drink. How would that possibly play out? Look, it's hard enough as a parent anyway, because kids do get around these laws. But we still have them and it's a lot easier as a parent. I think most parents would agree their life's made easier by minimum age restrictions on certain things. We have seatbelt laws. I mean, why do we have seatbelt laws? Why don't we just tell its parents' job to make sure their kids buckle up? The truth is its society and parents working hand in hand to try and keep children safe. And I think it also helps parents to be able to say that there are laws around this, and I expect you to follow the laws. So, I don't think it's an either or. Okay, well, I think that's a very good way to frame it. There are many, many precedents where we protect children. And why not do it here too? So let me end with a question I'd like to ask both of you. So, in this sea of concerns that we've discussed, is there a reason for optimism? And Kris, let me start, start with you. What do you think? Absolutely. I think the young people I've met that are leading among their peers are incredibly impressive and are armed with the research and their energy and their own lived experience in ways that are very compelling. At the same time, I think the vast amount of research that has now been compiled and translated and acted upon, whether in courtrooms or in state houses, it's becoming more, and we're all getting more steeped and aware of more nuanced information. And finally, I would just say, there is a tipping point. We are reaching as a society, adults and kids alike, we are reaching a tipping point where we can't withstand the pressure of technology in every aspect, every corner of our day, our life. And we want relief. We deserve relief. And I think that's what's going to take us over the finish line. Good. Well, I'm glad to hear those optimistic notes. Dimitri, what about you? I can find reasons to be optimistic. I mean, look, the reality is that technologies have enriched our lives in many ways. And I think if we put guardrails in place, we can make sure that future ones do even better. I have a piece coming out in JAMA Pediatrics around the use of AI, which people are very concerned about, I think rightly. But specifically, about the use of AI and people with intellectual developmental disabilities, making the use case, that there are ways in which it could be extremely beneficial to that population. A population I care deeply about in my role as the Chief Health Officer at Special Olympics International. And in particular, let's say in terms of the doctor patient interaction where it could facilitate their communication with their provider, and it could also help the provider better communicate with them. Look, that use case isn't going to be a priority for the purveyors of artificial intelligence. It's a small, non-lucrative use of a technology. But it's a good one. And if we created the right incentives and put in the right guardrails, we could find many other ways that technology can serve the needs of all of us going forward. I think the problem is that we've tended to be reactive rather than proactive. And to not start with the do no harm first premise, particularly when it comes to children. AI is another example of that where I hope we don't make the same mistake we made with social media. Bios Kris Perry is the executive director of the Children and Screens Institute. Kris most recently served as Senior Advisor to Governor Gavin Newsom of California and Deputy Secretary of the California Health and Human Services Agency where she led the development of the California Master Plan for Early Learning and Care and the expansion of access to high-quality early childhood programs. She led systems change efforts at the local, state and national levels in her roles as executive director of First 5 San Mateo, First 5 California and of the First Five Years Fund. Through it all, Perry has fought to protect children, improve and expand early learning programs, and increase investments in low-income children. Perry was instrumental in returning marriage equality to California after the landmark 2013 U.S. Supreme Court ruling Hollingsworth v. Perry, which she wrote about in her book Love on Trial (Roaring Forties Press, 2017). Dimitri Christakis, MD, MPH is the Children and Screens Institute's inaugural Chief Science Officer. He is also the George Adkins Professor at the University of Washington, Editor in Chief of JAMA Pediatrics, and the Chief Health Officer at Special Olympics International. Christakis is a leading expert on how media affects child health and development. He has published over 270 peer reviewed articles (h-index 101) including dozens of media-related studies and co-authored a groundbreaking book, The Elephant in the Living Room: Make Television Work for Your Kids. His work has been featured on Anderson Cooper 360, the Today Show, ABC, NBC, and CBS news as well as all major national newspapers. Christakis received his undergraduate degree at Yale University and his medical training at the University of Pennsylvania School of Medicine and completed his residency and Robert Wood Johnson Clinical Scholar Fellowship at the University of Washington School of Medicine. 

What if the key to reversing chronic disease, slowing cognitive decline, and boosting energy lies in the tiny powerhouses inside your cells—and we've finally found a way to protect them? We know mitochondria power our cells, but did you know they also create oxidative stress as they generate energy? Protecting mitochondrial health is critical—but most antioxidants can't reach inside the mitochondria where protection is needed most—until now. MitoQ, a scientifically advanced, mitochondria-targeted antioxidant developed by visionary researchers in New Zealand penetrates mitochondria up to 90%, offering protection where it's needed most. In this episode with Dr. Siobhan Mitchell, we dive into how MitoQ is transforming the way we tackle chronic disease, inflammation, and cognitive decline. From improving heart health to supporting brain function, MitoQ is changing the game. It's something I'm using personally and recommending to most of my patients. Listen in to discover how this powerful tool can help you support your patients at the cellular level—before symptoms even appear. ~DrKF Check out the show notes at https://tinyurl.com/2t55s3y3 for the full list of links and resources. GUEST DETAILS Dr Siobhan Mitchell, PhD., MitoQ Chief Scientific Officer Email: smitchell@mitoq.com Holding a PhD in neuroscience from SUNY Albany, Siobhan Mitchell has also completed a post-doctoral fellowship on brain aging at the University of Washington. She has over 15 years of clinical research experience, seven patents on mood and cognitive food products, and has authored over 50 papers on aging, brain health, nutrition, metabolic health and more. With a personal passion for brain aging research, Siobhan has worked on metabolic and skin health, appetite, sports physiology and of cellular health –which she now focuses on as the Chief Scientific Officer for research-backed cellular health company, MitoQ – creators of the world's first mitochondria-targeted antioxidant. THANKS TO OUR SPONSOR MitoQ: https://www.mitoQ.com/partner CustomerService@mitoq.com OFFER FOR NEW FRONTIERS LISTENERS Practitioners - Sign up to become a MitoQ Partner, access wholesale rates, and Unlock Cellular Health for your Patients by going to https://www.mitoq.com/partner CONNECT WITH DrKF Want more? Join our newsletter here: https://www.drkarafitzgerald.com/newsletter/ Or take our pop quiz and test your BioAge! https://www.drkarafitzgerald.com/bioagequiz YouTube: https://tinyurl.com/hjpc8daz Instagram: https://www.instagram.com/drkarafitzgerald/ Facebook: https://www.facebook.com/DrKaraFitzgerald/ DrKF Clinic: Patient consults with DrKF physicians including Younger You Concierge: https://tinyurl.com/yx4fjhkb Younger You book: https://tinyurl.com/mr4d9tym Better Broths and Healing Tonics book: https://tinyurl.com/3644mrfw

Dr. Hoffman continues his conversation with Dr. Garth Nicolson, Founder, President, Chief Scientific Officer, and Emeritus Research Professor of Molecular Pathology at the Institute for Molecular Medicine in Huntington Beach, California, and Research Advisor for Nutritional Therapeutics, makers of NTFactor.

Being a pharmacist is exciting–as long as you're willing to try new things. These are wise words from my returning guest on today's podcast, who has been paving the way for integrative pharmacy. Dr. Swathi Varanasi is an award-winning pharmacist passionate about the intersection of personalized medicine, patient outcomes, and innovation. With experience spanning patient care, biotech, research, academia, and consumer product goods, Dr. Swathi has paved the way for healthcare professionals to pursue non-traditional career paths through creating postdoctoral training programs, industry internships, and online educational programs. She co-founded and serves as Chief Scientific Officer of the Life Sciences Division at Element Apothec, and serves as a Principal Investigator at contract research organization, Citruslabs. Dr. Swathi received her Doctor of Pharmacy (PharmD) at the Medical University of South Carolina and Bachelor of Arts (BA) at Carleton College. She was the first-ever pharmacist in the United States with formal residency training to specialize in integrative medicine and preventative health. She also completed a postdoctoral fellowship in Medical Affairs in biotech and has training in nutrition from Cornell University. Dr. Swathi has served as faculty and guest lectures at colleges and universities across the country. She is an advisor and consultant for a number of for-profit and nonprofit organizations aiming to make the world a healthier place for us to live–and thrive. She has been published in peer-reviewed academic journals and featured in Yahoo, mindbodygreen, Well+Good, Entrepreneur, Forbes Health, and more. In 2023, Dr. Swathi was voted one of the 50 Most Influential Leaders in Pharmacy. Connect with Dr. Swathi via: Email: swathimvaranasi@gmail.com FB: Doctor Swathi IG: @doctorswathi Linked In:Dr. Swathi Varanasi Check out our earlier episode here: https://www.marinabuksov.com/s03e03-paving-the-unconventional-path-with-integrative-pharmacist-dr-swathi-varanasi/ Visit https://marinabuksov.com for more holistic content. Music from https://www.purple-planet.com. Disclaimer: Statements herein have not been evaluated by the Food and Drug Administration. Products listed are not intended to diagnose, treat, cure, or prevent any diseases.

Hier kommt sie endlich, die Sonderfolge der SXSW – eine Ausgabe, die eigentlich live vor Publikum hätte stattfinden sollen. Ja, das Gespräch zwischen Felix und Steffen Bolz fand wie geplant auf der wohl wichtigsten Innovationskonferenz der Welt statt – nur die Technik im German House wollte nicht mitziehen, am Ende war auf der Speicherkarte statt eines spannenden Talks nur blechernes Rauschen zu hören. Zum Glück hat Steffen Bolz sich schon das ein oder andere abgeschaut von der Grundentspanntheit, mit der seine kanadischen Landsleute durchs Leben gehen, und hat Felix daher noch ein zweites Mal getroffen.

Join Adam Draper, founder of Boost VC and host of the "Can't Be Done" Podcast, as he chats with James Sinka, Chief Scientific Officer at BIO Protocol. They dive into sci-fi novels, leadership, and the challenges Sinka faced on his journey. Beyond personal insights, they explore DeSci, the crucial role of scientists, and how researchers can secure financial rewards alongside recognition for groundbreaking work. Don't miss this inspiring conversation on science, motivation, and innovation!Science Lead @ Bio.xyz - YCW19 Alum, repeat founder, and chemist. Connect with James SinkaBio Protocol https://www.bio.xyz/Bio Protocol on LinkedIn https://www.linkedin.com/company/bioprotocol/Bio Protocol on X https://x.com/bioprotocolJames on LinkedIn https://www.linkedin.com/in/jamessinka/James on X  https://x.com/jamessinka Connect with Boost VCBoost VC https://www.boost.vc/Boost VC on LinkedIn https://www.linkedin.com/company/boost-vc/?viewAsMember=trueBoost VC on X https://x.com/BoostVC?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5EauthorBoost VC on Instagram https://www.instagram.com/boost_vc/?hl=en

Dr. Janine Sengstack is the Chief Scientific Officer and co-founder of Junevity, a company created in 2023 with the mission of extending health span and lifespan through what they term "Cell Reset therapeutics." The company recently secured $10 million in seed funding.In this episode, Chris and Janine explore the innovative platform Janine developed during her PhD work in Hao Li's lab at UCSF, which now forms the foundation of Junevity's therapeutic approach. They discuss how the company uses computational and experimental methods to identify transcription factors that can "reset" cells from a diseased, aged state back to a healthy state while maintaining cell identity. Janine explains how Junevity is developing siRNA therapeutics targeting these transcription factors to treat age-related diseases, with a focus on metabolic conditions and other disorders that impact longevity.The Finer Details:The development of the Reset platform during Janine's PhD work and its evolution into Junevity's therapeutic approachHow transcription factors act as "managers" in cells, regulating many other genesUsing AI and machine learning to identify the right transcription factors to target based on disease and tissue-specific dataThe validation process for siRNA therapeutic candidates in cell and animal modelsJunevity's focus on diseases with large-scale transcriptional dysregulation, including type 2 diabetes, obesity, muscle wasting diseases, and osteoarthritisThe advantages of siRNA as a therapeutic modality for targeting traditionally "undruggable" transcription factorsJunevity's business strategy and timeline, with clinical trials potentially beginning in 2026Quotes:"We tackled this high risk, high reward PhD project: we were inspired by the Yamanaka factors to say, 'Okay, let's find brand new transcription factors that we can target to take cells from a diseased, old state and bring them back to a healthy state while keeping them the same cell type, never turning them into a stem cell.'""Transcription factors: I like to think of them as managers in the cell.""We think the advent of modern AI and machine learning tools to better analyze what they regulate, plus siRNA as a really well-proven therapeutic modality, really unlocks the ability to target transcription factors and really make powerful therapeutics with them.""We're thinking about using transcriptional regulation as a way to come up with novel therapeutics to treat diseases that have a big impact on people's health span and lifespan.""We want to advance our programs towards development candidates, which basically means the drug entity, and move them forward towards clinical development as fast as possible.""I would love if we had multiple siRNA drugs on the market, ideally, or in late stages of development for a wide range of longevity-related diseases... We think that there's really huge potential here for making a big impact on a lot of different really complicated diseases."Linkshttps://www.junevity.com

In this short segment of the Revenue Builders Podcast, we revisit the discussion with Parm Uppal, CRO at Benchling, to discuss the critical shift from measuring sales activities to tracking accomplishments. Parm shares insights on setting clear expectations for reps, training them for high-impact meetings, and aligning their daily actions with business outcomes. The conversation explores strategies for reaching economic buyers, adapting to shifting funding landscapes, and simplifying sales execution for maximum effectiveness.KEY TAKEAWAYS[00:00:26] The power of simplifying expectations for sales reps.[00:01:19] Training reps for high-impact meetings to close deals.[00:02:13] Why accomplishments matter more than activity metrics.[00:03:16] Aligning rep performance with business goals using a proven framework.[00:04:52] Adapting to shifts in funding and decision-making authority.[00:05:45] Setting clear expectations: the three-to-four things reps must always know.[00:07:07] Keeping sales execution simple and focusing on small wins.QUOTES[00:01:45] “If we know these are the toughest meetings, we have a duty as leaders to be training reps for them.”[00:02:32] “If you got an EB meeting, chances are you already have a champion. To get a champion, you probably did proper discovery.”[00:04:07] “Are you the chief problem officer, or are you just running deals? Your sales strategy depends on how well you define the problem.”[00:05:45] “I want my reps to wake up and immediately know the three to four things I expect from them—without having to write them down.”[00:07:24] “We keep it simple: What's the biggest red flag in MEDDIC today, and who do we take the Three Whys to?”Listen to the full conversation through the link below.https://revenue-builders.simplecast.com/episodes/data-driven-decision-making-with-parm-uppalEnjoying the podcast? Sign up to receive new episodes straight to your inbox:https://hubs.li/Q02R10xN0Check out John McMahon's book here:Amazon Link: https://a.co/d/1K7DDC4Check out Force Management's Ascender platform here: https://my.ascender.co/Ascender/Force Management is hiring for a Sales Director. Apply here: https://hubs.li/Q02Zb8WG0Read Force Management's eBook: https://www.forcemanagement.com/roi-of-sales-messaging

Dr. Drew is LIVE in Washington, DC, interviewing members of the Trump admin team including Sec. Robert F. Kennedy Jr, Karoline Leavitt, May Mailman, Sec. Linda McMahon. He's joined by special guest Dr. Peter McCullough. Dr. Peter McCullough is an internist, cardiologist, epidemiologist, and the Chief Scientific Officer at The Wellness Company. As an expert on cardiovascular medicine with over 30 years of experience, Dr. McCullough has spoken widely about the heart-related risks of mRNA. He is the co-author of The Courage To Face COVID-19: Preventing Hospitalization and Death While Battling the Bio-Pharmaceutical Complex. Follow Dr. McCullough at https://x.com/P_McCulloughMD and learn more at https://PeterMcCulloughMD.com Dr. Stephanie Venn-Watson is a co-founder of Seraphina Therapeutics. She holds a Doctor of Veterinary Medicine from Tufts University, a Master of Public Health from Emory University, and completed a National Research Council Associateship with the Armed Forces Medical Intelligence Center. As a Technical Agent for DARPA and researcher with the U.S. Navy Marine Mammal Program, she discovered C15:0's role in preventing Cellular Fragility Syndrome. This led her to co-found Seraphina Therapeutics, developing the fatty15 supplement. Find more at https://drdrew.com/fatty15 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at https://drdrew.com/sponsors  • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at https://drdrew.com/fatty15 • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at https://drdrew.com/paleovalley • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (https://kalebnation.com) and Susan Pinsky (https://twitter.com/firstladyoflove). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com AI is revolutionizing healthcare by offering new ways to solve complex problems, emphasizing data-driven solutions over traditional hypothesis-based approaches. In this episode, Dr. Sam Perli, Chief Scientific Officer and founding member of Thinkhat, discusses how his company is building an AI-powered venture studio to launch innovative healthcare and life sciences companies. Thinkhat serves physicians with its Noki co-pilot for automated tasks, patients with noninvasive monitoring solutions, and pharmaceutical companies with its Encode AI engine for optimizing sequence medicines. Dr. Perli acknowledges skepticism around AI but highlights its potential to solve complex problems like protein folding and neurodegenerative diseases. He encourages openness to AI and suggests cost-effective development strategies, including tapping into global talent pools and leveraging resources in places like Puerto Rico. Tune in and learn how Thinkhat leverages AI to address previously unsolvable problems in medicine, providing a diverse set of solutions across the healthcare industry! Resources:  Connect and follow Dr. Sam Perli on LinkedIn. Learn more about Thinkhat on their LinkedIn and website. Email Thinkhat directly here. Email Sam here. Fast Track Your Business Growth: Outcomes Rocket is a full-service marketing agency focused on helping healthcare organizations like yours maximize your impact and accelerate growth. Learn more at outcomesrocket.com

In this bonus episode from the Applied Ergonomics Conference 2025, Dr. Karl Zelik of Vanderbilt University shares insightful perspectives on innovation in biomechanics and wearable technology. Drawing from his extensive experience as co-director of the Center for Rehabilitation Engineering and Assistive Technology and as Chief Scientific Officer of HeroWear, Zelik discusses how to identify meaningful advancements versus mere industry hype. He provides practical guidance on creating sustainable, impactful solutions that enhance workplace health, safety, and productivity. Zelik's keynote underscores the importance of informed innovation to truly improve well-being across industries and society.

Did you know that patient registries play a vital role in improving kidney disease treatment and outcomes? In this episode, we're diving into the KidneyCARE Study—a patient registry that uses real-world data to better care for people with kidney disease. We sat down with experts as they explained what a patient registry is and why people with kidney disease may want to join the KidneyCARE Study. In today's episode we heard from:    Kerry K. Willis PhD- Dr Willis is the Chief Scientific Officer of the National Kidney Foundation (NKF). Since joining NKF in 1998, her major focus has been on the analysis and application of clinical evidence to improve care and outcomes for people living with kidney disease. She oversees all NKF-sponsored research and professional education programs, including the Spring Clinical Meetings; population health programs that facilitate health system and practice engagement around CKD as a quality improvement target; the Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice guidelines; KDOQI quality measurement initiative; and four peer-reviewed journals devoted to chronic kidney disease. She led the development of and currently manages the Kidney CARE (Community Access to Research Equity) Study, the first national CKD patient registry to combine patient-reported data with clinical data from electronic health records.     Rachel Claudin, BS, CCLS- Rachel Claudin is the Patient-Centered Research Director at the National Kidney Foundation (NKF). Her main work for the past three years has been focused on the advancement of the KidneyCARE Study. As a person living with Lupus Nephritis, she is excited for the patient-entered data collected by the Study to increase and improve kidney care research. Previous to the NKF, Rachel worked in hospital and hospice settings advocating for patients utilizing the shared decision-making model of healthcare. Cari Maxwell- Cari has lived with Polycystic Kidney Disease (ADPKD) since 1989, and her personal experience, along with the experiences of her father and two siblings, fuels her advocacy for advancements in PKD treatment. She participated in the Tolvaptan Reprise trial, which led to the first-ever FDA-approved treatment for ADPKD—a treatment she continues to benefit from today. As a member of the NKF Kidney Advocacy Committee, Cari is passionate about promoting patient education, early detection, and scientific progress through patient-centered clinical research. She is dedicated to ensuring that others have access to life-changing treatments and are empowered to advocate for their health through proactive care. Cari currently works in health care cost containment strategies, where she applies her expertise to enhance patient access and outcomes. Sandy Gilbert PhD- Sandy Gilbert is the Senior Director of Patient Outcomes Research at the National Kidney Foundation (NKF), where she manages the KidneyCARE (Community Access to Research Equity)™ Study. Since joining NKF in 2024, her focus has been on developing and overseeing this pioneering national kidney disease patient registry, the first to integrate patient-reported data with clinical data from electronic health records. The goal of the Registry is to generate critical insights into disease progression, treatment outcomes, and health disparities, in support of NKF's mission to improve kidney health and drive innovation in kidney research and healthcare. Sandy works closely with teams of researchers and health system partners to expand the study's reach and ensure that it reflects the needs of diverse patient populations, including those from underserved communities. Additional Resources: KidneyCare Study Information Contact Information: Call: 212.889.2210 ext.134 M-F 10am-4pm CT  Email: kidneycarestudy@kidney.org   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

Dr. Eric Kmiec is Director of the Gene Editing Institute of the Helen F. Graham Cancer and Research Institute at Christiana Care Health System. He also holds faculty appointments at the University of Delaware and the Wistar Institute. Eric and his colleagues are working to develop new ways to treat cancer by destroying the genes that cause cancer cells to be resistant to typical therapies like chemotherapy, radiation, or immunotherapy. Throughout his life, Eric has enjoyed sports. He particularly likes playing baseball and hockey, and he still plays baseball competitively in a league in Philadelphia. Eric also spends much of his time doing landscaping and yard work. He Received his B.A. in Microbiology from Rutgers University, his M.S. in Cell Biology and Biochemistry from Southern Illinois University, and his Ph.D. in Molecular Biology and Biochemistry from the University of Florida School of Medicine. He conducted postdoctoral research at the University of Rochester before joining the faculty at the University of California, Davis in 1987. Since then, he has served on the faculty of Thomas Jefferson University, the University of Delaware, and Delaware State University. In addition, Eric founded, consulted for, and served as Vice President of Kimeragen, Inc., he was Chief Scientific Advisor for the Genomics Division of Tapestry Pharmaceuticals, was an Eminent Scholar and Director of the Marshall University Institute for Interdisciplinary Research, and also served as Co-Founder, Chief Scientific Officer, and a Board Member of OrphageniX. Eric has received numerous awards and honors over the course of his career, including receipt of the 2012 Proudford Foundation Unsung Hero Award in Sickle Cell Disease, designation as an Honorary Commander of the 436th Air Wing at Dover Air Force Base in 2013 and 2014, and also induction into the Southern Illinois University, Edwardsville Alumni Hall of Fame in 2012. Further, Eric and the team at the Gene Editing Institute were recently awarded the inaugural Life Sciences and Bio Innovation Award from the Philadelphia-Israeli Chamber of Commerce. In our interview, Eric shared his experiences in life and science.

Aging often brings increased health risks, but groundbreaking science is transforming how we understand and potentially reverse this process. Could stem cells and advanced immunotherapy help the human body regain youthful function and vitality? Join us as we sit down with Dr. Thomas Ichim, Chief Scientific Officer at Immorta Bio, a pioneering company at the forefront of regenerative medicine and longevity science. With over two decades of biotech entrepreneurship, Dr. Ichim has successfully launched and grown numerous innovative biotech ventures, cementing his role as a visionary in stem cell science and immuno-oncology. In this fascinating discussion, you'll learn: Ichim's personal mission and relentless commitment to alleviating human suffering. How cutting-edge stem cell therapies are revolutionizing treatments for various aging-related conditions. The powerful synergy between AI technology and biotechnology that's driving innovation in regenerative medicine. Promising novel therapies being developed for precise, effective cancer treatment. Ready to explore how science is reshaping the possibilities of human longevity? Dive into the episode now! To discover more about Dr. Ichim's groundbreaking research at Immorta Bio, click here. And don't forget to follow him on X @exosome for the latest breakthroughs and insights. Episode also available on Apple Podcasts: https://apple.co/38oMlMr

Join me for a fascinating conversation around an exciting breakthrough in dementia detection that's offering real hope for early intervention. Dr. Hans Frykman, Chief Scientific Officer at Neurocode Laboratories, is here to share groundbreaking insights into cutting-edge biomarkers that can identify pathology associated with Alzheimer's disease before symptoms even appear. What's even more fascinating is how these same tools are revealing neuroinflammation caused by infections, including COVID, Lyme disease, and mold exposure—issues that are incredibly relevant in functional medicine today. The assays Dr. Frykman and his team have developed, and continue to research, are transforming the way we think about diagnosing and addressing neurodegeneration. We're talking about a potential game-changer that allows us to intervene earlier, reverse damage, and ultimately improve the trajectory of these conditions. This is an extraordinary time in science and medicine, and the work we're discussing today is at the forefront of it all. Don't miss out on how this could reshape your practice. ~DrKF Check out the show notes at https://tinyurl.com/2t55s3y3 for the full list of links and resources. GUEST DETAILS Dr. Hans Frykman, MD PhD FRCPC hfrykman@neurocode.com Hans Frykman MD, Ph.D., FRCPC is the founder, CEO, and medical director of BC Neuroimmunology Lab located in the UBC hospital on the University of BC campus in Vancouver BC. He is the medical director for Lykke Lab a genetics laboratory also on the University of BC campus. Also, he is the CSO for Neurocode Lab Inc. in Bellingham WA, a high-complexity, specialty lab focused on neuroimmunology and biomarkers in neurodegeneration. Dr. Frykman has a clinical faculty position at the University of British Columbia, Faculty of Medicine, Division of Neurology. THANK YOU TO OUR SPONSORS DIAMOND DUTCH: https://dutchtest.com/for-providers Biotics Research: https://www.bioticsresearch.com/ GOLD TimeLine Nutrition: https://tinyurl.com/bdzx2xms Vibrant Wellness: https://www.vibrant-wellness.com/ EXCLUSIVE OFFERS FROM OUR SPONSORS OneSkin: Get 15% off OneSkin with the code DRKARA at oneskin.co/DRKARA Try Qualia NAD+ for up to 50% off! Visit http://qualialife.com/kara15 and use code KARA15 at checkout for an additional 15% off your entire purchase! Why MitoQ's mitochondria-targeting is a critical step for your healthspan and longevity strategy. https://tinyurl.com/2b5benmd Want more? CONNECT WITH DrKF Join our newsletter here: https://www.drkarafitzgerald.com/newsletter/ Or take our pop quiz and test your BioAge! https://www.drkarafitzgerald.com/bioagequiz YouTube: https://tinyurl.com/hjpc8daz Instagram: https://www.instagram.com/drkarafitzgerald/ Facebook: https://www.facebook.com/DrKaraFitzgerald/ DrKF Clinic: Patient consults with DrKF physicians including Younger You Concierge: https://tinyurl.com/yx4fjhkb Younger You book: https://tinyurl.com/mr4d9tym Better Broths and Healing Tonics book: https://tinyurl.com/3644mrfw

In this episode, we explore the complex and often debated concept of value in prescription drugs. They discuss how different stakeholders—payers, manufacturers, providers, regulators, and patients—define value, and how methodologies like health technology assessments (HTA) and cost-effectiveness analyses shape drug pricing and access. With insights from leading experts, the conversation examines the controversies surrounding value-based pricing, including the role of real-world evidence, quality-adjusted life years (QALYs), and innovation incentives. Can we strike a balance between affordability, innovation, and patient access? And what does the future hold for value-based drug pricing in the U.S.? Tune in for a deep dive into one of the most critical issues in healthcare today. Daniel Ollendorf, Chief Scientific Officer and Director of HTA Methods and Engagement Lou Garrison, Professor Emeritus at University of Washington CHOICE Institute for Clinical and Economic Review (ICER) FDA GLP-1 Drugs Medicare Biosimilars Generics Versus Biosimilars PBMs (Pharmacy Benefit Managers) 340B Drug Pricing Program Questions or comments?Email us at comments@prescriptionforbetteraccess.com.Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

In this episode of Skin Anarchy, we sit down with Dr. Jérémie Soeur, Chief Scientific Officer, and Jennifer Hessel, General Manager of North America at Cellcosmet, to explore how cutting-edge research is redefining skincare. With a science-first approach, Cellcosmet is setting new standards in microbiome support, peptide technology, and cellular rejuvenation.Dr. Soeur explains how Cellcosmet's CytoPEP™ technology harnesses over 5,000 peptides, proteins, amino acids, and enzymes to target multiple skin-aging pathways. Unlike brands that rely on isolated ingredients, Cellcosmet's approach activates a network of biological functions to restore skin vitality. Their CellControl™ method ensures the peptides retain their structure and effectiveness throughout formulation, a step often overlooked in traditional skincare.Jennifer Hessel highlights the importance of microbiome research, explaining how Cellcosmet sequences bacteria before and after product use to measure its real impact on skin health. Their formulations not only nourish the microbiome but also protect against environmental stressors, making them a true game-changer in skincare.What sets Swiss skincare apart? Stringent quality control. Cellcosmet follows some of the world's strictest regulations, maintaining 100 times lower microbial contamination levels than standard beauty products, ensuring pharmaceutical-grade purity.As skincare personalization continues to evolve, Cellcosmet is pioneering the future—using microbiome sequencing and epigenetic research to develop tailored solutions for individual skin needs.Tune in to hear how science is driving the next era of beauty and why Cellcosmet is revolutionizing the way we think about skincare.SHOP Cellcosmet and use code SAcellcosmet15 for 15% off your first purchase!To learn more about Cellcosmet, visit their website and social media. Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform. Reach out to us through email with any questions.Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.

Hosted by Mike Simmons. In this episode of #BigImpactAstronomy, Mike Simmons talks with Olayinka Fagbemiro about her inspiring work bringing STEM education to underserved communities in Nigeria. From IDP camps to classrooms, she's empowering young minds—especially girls—to see a future in science.    (From the Karman Project) Olayinka Fagbemiro has dedicated over 17 years to advancing space science and technology as the Chief Scientific Officer at the Nigerian Space Agency. She currently leads the Space Education Outreach Unit and is a vital member of the Planning, Policy, and Research team.  Her leadership extends to her role as the Founder, CEO and National Coordinator, Astronomers Without Borders Nigeria, an NGO leveraging astronomy to foster STEM education and address educational inequalities across Nigeria. Olayinka is pursuing a PhD in Geoinformatics at the African University of Science and Technology, where her research focuses on the use of deep learning algorithms for urban development studies. Her expertise in spatial sciences is further augmented by her academic background, with a B.Sc. in Computer Science from the University of Ilorin and an M.Sc. in Technology Management from Obafemi Awolowo University.   Mike Simmons is the founder of Astronomy for Equity ( https://bmsis.org/astro4equity/ ). Others on the team, including people around the world in astronomy and space exploration, authors and philosophers, designers and artists and more will be added as the website is developed.   We've added a new way to donate to 365 Days of Astronomy to support editing, hosting, and production costs.  Just visit: https://www.patreon.com/365DaysOfAstronomy and donate as much as you can! Share the podcast with your friends and send the Patreon link to them too!  Every bit helps! Thank you! ------------------------------------ Do go visit http://www.redbubble.com/people/CosmoQuestX/shop for cool Astronomy Cast and CosmoQuest t-shirts, coffee mugs and other awesomeness! http://cosmoquest.org/Donate This show is made possible through your donations.  Thank you! (Haven't donated? It's not too late! Just click!) ------------------------------------ The 365 Days of Astronomy Podcast is produced by the Planetary Science Institute. http://www.psi.edu Visit us on the web at 365DaysOfAstronomy.org or email us at info@365DaysOfAstronomy.org.

Send me a text! I'd LOVE to hear your feedback on this episode!Important Links:Check out all the research on melatonin, the world's first natural, plant melatonin, and more with Symphony Natural Health here:  https://symphonynaturalhealth.com/Join my Substack, where you'll get a glimpse of my upcoming book:https://sandykruse.substack.com/Interesting PubMed article relating to our discussion:  https://pmc.ncbi.nlm.nih.gov/articles/PMC6362935/Contact me directly here: sandy@sandyknutrition.ca or sandy@tkgpartners.com.Dr. Deanna Minich is a Certified Functional Medicine Practitioner, a nutrition scientist, international lecturer, teacher, and author, with over twenty years of experience in academia and in the food and dietary supplement industries.  She is also the Chief Scientific Officer for Symphony Natural Health, the makers of Herbatonin, the world's first plant melatonin.Melatonin's full potential extends beyond sleep, functioning as a powerful circadian nutrient with antioxidant, anti-inflammatory, and mitochondrial-protective properties. Dr. Deanna Minich reveals how this misunderstood molecule could be the key to longevity and better health when understood and used correctly.• Melatonin is primarily a circadian rhythm signaler that helps synchronize cellular clocks throughout the body• Natural melatonin production declines drastically with age—by our 50s we produce only 10% of what we had as adolescents• Light exposure significantly impacts melatonin—morning light turns it off while evening darkness triggers production• Eye color affects melatonin sensitivity—people with lighter eyes experience 17% more melatonin suppression from artificial light• Physiological doses (0.3-0.9mg) are more appropriate for general wellness than higher pharmacological doses• Plant-based melatonin (erbitonin) shows significantly greater anti-inflammatory and antioxidant effects than synthetic versions• Melatonin concentrates in the mitochondria, making it a powerful protector against cellular damage and potentially beneficial in cancer therapy• Full moon cycles naturally affect melatonin production and sleep patterns regardless of direct moonlight exposureIf you enjoyed this episode, please share it with someone who might benefit, and rate, review, and subscribe to my podcast. For more resources, visit symphonynaturalhealth.com where you'll find educational mSupport the showPlease rate & review my podcast with a few kind words on Apple or Spotify. Subscribe wherever you listen, share this episode with a friend, and follow me below. This truly gives back & helps me keep bringing amazing guests & topics every week.Instagram: https://www.instagram.com/sandyknutrition/Facebook Page: https://www.facebook.com/sandyknutritionTikTok: https://www.tiktok.com/@sandyknutritionYouTube: https://www.youtube.com/channel/UCIh48ov-SgbSUXsVeLL2qAgRumble: https://rumble.com/c/c-5461001Linkedin: https://www.linkedin.com/in/sandyknutrition/Substack: https://sandykruse.substack.com/Podcast Website: https://sandykruse.ca

Have you ever considered silver as a line of treatment?  Not only can topical silver-based products help with wound healing, but there's actually a TON of immune-boosting benefits from taking colloidal silver, too.  Expert and leader at Silver Biotics– Steve Revelli joins me today to show you how silver is redefining health, energy, and strength for so many people.  You already know I'm a big proponent of preventative medicine, especially when it comes to lowering inflammation, supporting gut and whole-body health, and healing our bodies naturally and effectively...  And silver products can help us do just that!  Silver Biotics has tons of diverse products that boost immune system health and benefit the whole body.  So check out the podcast here to discover the massive advantages of using silver, and grab a discount for your first order of Silver Biotics!  Steve Revelli Steve Revelli is the Chief Scientific Officer and R&D leader at American Biotech Labs. He's also a retired educator and former Adjunct Professor, bringing 30+ years of science and health education to his role. At Silver Biotics, he pioneers clean cosmetics and wound care products, merging science with wellness. IN THIS EPISODE What is colloidal silver, and how does it work? How silver is used in modern science and medicine Silver technology's interaction with the immune system  The importance of supplementation- particularly for women during midlife Unpacking myths around the use of colloidal silver  The future technology and uses of silver in medicine  Using silver for acute conditions or preventative measures  About Silver Biotics, and their effective supplements and products  QUOTES “What happens is you give an immune supplement that takes care of all the bioload and allows the immune system to do what it normally does and function a lot more efficiently, and that's what our silver does.” “What the immune system support does with our silver is it takes care of those pathogens. So you can have a good, healthy population of probiotics always in your gut.”  “The immune support that the silver does– it kills pathogens. It'll kill pathogens anywhere in the body.” RESOURCES MENTIONED Get Your Silver Biotics HERE ++ use code: DRMARIZA for 30% off your first order! Silver Biotics on Instagram  Silver Biotics on Facebook  RELATED EPISODES  #610: The Benefits of Spirulina and Chlorella for More Energy, Longevity, And Immunity with Catharine Arnston 591: Post Viral Syndromes, Your Immune System, And Your Hormones in Midlife with Dr. Jessica Drummond #334: 3 Immune-Boosting Habits That Are Non-Negotiable Right Now

In today's episode, we dive into the wonders of T-cell immunology technology and how it impacts early treatment interventions with long-time drug developer Dr. Nigel McCracken. As the Chief Operating Officer of Virax Biolabs, Dr. McCracken has more than 25 years of research and development experience in this diverse field – including oncology and infectious disease… Virax Biolabs is committed to revolutionizing global health by accelerating the development of more effective vaccines. How do they achieve this? By harnessing cutting-edge diagnostics to power a groundbreaking T-cell immunology platform, enabling early detection of post-viral syndromes and conditions linked to chronic inflammation and T-cell exhaustion. Before joining Virax, Dr. McCracken served as Chief Scientific Officer at BerGenBio ASA, where he led the development of companion diagnostics and assay strategies. Prior to that, he was COO at NuCana PLC, a clinical-stage biopharmaceutical company dedicated to improving cancer treatment outcomes. In this role, he oversaw business operations, research and development, and the execution of corporate strategy. Tune in now to learn about: The importance of early diagnosis when it comes to immune system dysfunction. How the complementary system interacts with the immune system.  The typical role that T-cells play in infections.  Why chronic health problems are on the rise, and what this could mean for the future of healthcare. You can follow along with Dr. McCracken's work at Virax Biolabs here! Episode also available on Apple Podcasts: https://apple.co/30PvU9C Upgrade Your Wallet Game with Ekster!  Get the sleek, smart wallet you deserve—and save while you're at it! Use coupon code FINDINGGENIUS at checkout or shop now with this exclusive link: ekster.com?sca_ref=4822922.DtoeXHFUmQ5  Smarter, slimmer, better. Don't miss out!

Today, I am honored to connect with Catharine Arnston, the Founder, CEO, and Chief Scientific Officer of ENERGYbits.  I was fortunate to have had the opportunity to meet Catharine in person this past July at KetoCon in Austin. Much of her work focuses on optimizing mitochondrial function and recognizing that mitochondria are pivotal to our metabolism, longevity, brain and gut health, sleep, digestion, and almost everything else.  In our conversation, we dive into what got Catharine passionate about algae. We speak about her transition from a corporate economic development role into a budding entrepreneur, the distinctions between micro and macroalgae, and the more than 100,000 studies that have been done- especially in Asia, that show algae are of the most alkaline and nutrient-dense foods available. We differentiate between spirulina and chlorella and explain their roles in our mitochondrial health. We also discuss how our stressful lifestyles impact our cellular health and talk about autophagy, red light therapy, immune function, and more. I hope you enjoy today's eye-opening discussion about the value of consuming microalgae daily. Stay tuned to find out what microalgae are and what they do to keep you healthy! IN THIS EPISODE YOU WILL LEARN: How an issue with her sister's health resulted in Catharine becoming passionate about algae as a food source. Algae is a food, not a supplement.  How do macroalgae differ from algae? Spirulina and chlorella are grown as fresh-water crops. So they contain no iodine. They also have no lectins or oxalates.  Catharine explains why algae are some of the most nutrient-dense foods available.  Why are algae critical for maintaining mitochondrial health? Consuming microalgae every day means you do not have to deteriorate as you age. What makes spirulina's absorption rate so high?  The health benefits of consuming chlorella. Catherine explains how spirulina and chlorella differ and work together synergistically. How does chlorella differ from activated charcoal? What are the benefits of having chlorophyll in your body when exposed to red light? Catharine unpacks the immune-supportive aspects of spirulina and chlorella. Spirulina and chlorella are keto-friendly, can be used when fasting intermittently, and are safe for people with diabetes.   Connect with Cynthia Thurlow Follow on Twitter, Instagram & LinkedIn Check out Cynthia's website  Connect with Dr. Catharine Arnston On her website (Use the 20% discount code: CYNTHIATHURLOW On Facebook On Instagram (@energybits) On Twitter (@energybits)  Resources: Why Algae is a Food, Not a Supplement Article Algae Article Chlorophyll Article Collagen Article